BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Topór-Mądry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C; Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91. [PMID: 28983565 DOI: 10.1001/jamaoncol.2017.3055] [Cited by in Crossref: 924] [Cited by in F6Publishing: 1027] [Article Influence: 231.0] [Reference Citation Analysis]
Number Citing Articles
1 Gan T, Bambrick H, Tong S, Hu W. Air pollution and liver cancer: A systematic review. J Environ Sci (China) 2023;126:817-26. [PMID: 36503807 DOI: 10.1016/j.jes.2022.05.037] [Reference Citation Analysis]
2 Gao X, Xu M, Wang H, Xia Z, Sun H, Liu M, Zhao S, Yang F, Niu Z, Gao H, Zhu H, Lu J, Zhou X. Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma. Gene 2023;855:147133. [PMID: 36565797 DOI: 10.1016/j.gene.2022.147133] [Reference Citation Analysis]
3 Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. Cancer 2023;129:590-9. [PMID: 36426410 DOI: 10.1002/cncr.34559] [Reference Citation Analysis]
4 Buch S, Innes H, Lutz PL, Nischalke HD, Marquardt JU, Fischer J, Weiss KH, Rosendahl J, Marot A, Krawczyk M, Casper M, Lammert F, Eyer F, Vogel A, Marhenke S, von Felden J, Sharma R, Atkinson SR, McQuillin A, Nattermann J, Schafmayer C, Franke A, Strassburg C, Rietschel M, Altmann H, Sulk S, Thangapandi VR, Brosch M, Lackner C, Stauber RE, Canbay A, Link A, Reiberger T, Mandorfer M, Semmler G, Scheiner B, Datz C, Romeo S, Ginanni Corradini S, Irving WL, Morling JR, Guha IN, Barnes E, Ansari MA, Quistrebert J, Valenti L, Müller SA, Morgan MY, Dufour JF, Trebicka J, Berg T, Deltenre P, Mueller S, Hampe J, Stickel F. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut 2023;72:381-91. [PMID: 35788059 DOI: 10.1136/gutjnl-2022-327196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Tsai PC, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Chen CY, Yu ML; T-COACH Study Group. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol 2023;78:281-92. [PMID: 36208843 DOI: 10.1016/j.jhep.2022.09.019] [Reference Citation Analysis]
6 Abdelhamed W, El-Kassas M. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful. J Viral Hepat 2023;30:148-59. [PMID: 36461645 DOI: 10.1111/jvh.13778] [Reference Citation Analysis]
7 Davitkov P, Hoffman K, Falck-Ytter Y, Wilson B, Stojadinovikj G, Anthony DD, Cohen SM, Cooper G. Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study. PLoS One 2023;18:e0280647. [PMID: 36693057 DOI: 10.1371/journal.pone.0280647] [Reference Citation Analysis]
8 Steinmann SM, Sánchez-martín A, Tanzer E, Cigliano A, Pes GM, Simile MM, Desaubry L, Marin JJ, Evert M, Calvisi DF. eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. IJMS 2023;24:2055. [DOI: 10.3390/ijms24032055] [Reference Citation Analysis]
9 Xu Y, Zheng B, Liu X, Wu T, Ju J, Wang S, Lian Y, Zhang H, Liang T, Sang Y, Jiang R, Wang G, Ren J, Chen T. Improving artificial intelligence pipeline for liver malignancy diagnosis using ultrasound images and video frames. Brief Bioinform 2023;24:bbac569. [PMID: 36575566 DOI: 10.1093/bib/bbac569] [Reference Citation Analysis]
10 Shen C, Jiang X, Li M, Luo Y. Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers (Basel) 2023;15. [PMID: 36672482 DOI: 10.3390/cancers15020533] [Reference Citation Analysis]
11 Lu Z, Huang Y, Huang J, Ni HH, Luo T, Wei X, Bai X, Qi L, Xiang B. High Platelet Count is a Potential Prognostic Factor of the Early Recurrence of Hepatocellular Carcinoma in the Presence of Circulating Tumor Cells. J Hepatocell Carcinoma 2023;10:57-68. [PMID: 36685111 DOI: 10.2147/JHC.S398591] [Reference Citation Analysis]
12 Huang J, Lucero-Prisno DE 3rd, Zhang L, Xu W, Wong SH, Ng SC, Wong MCS. Updated epidemiology of gastrointestinal cancers in East Asia. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36631716 DOI: 10.1038/s41575-022-00726-3] [Reference Citation Analysis]
13 Santagata S, Castaldo D, Rea G, Napolitano M, Capiluongo A, D'alterio C, Trotta AM, Ieranò C, Portella L, Tatangelo F, Albino V, Guarino R, Cutolo C, Izzo F, Scala S. Hepatocellular carcinoma (HCC) Tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) Tumor microenvironment.. [DOI: 10.21203/rs.3.rs-2419131/v1] [Reference Citation Analysis]
14 Kraglund F, Villadsen GE, Jepsen P. Effects of Curative-Intent Treatments on Hepatocellular Carcinoma Survival in Alcohol-Related Cirrhosis: A Nationwide Study. Clin Epidemiol 2023;15:39-48. [PMID: 36636732 DOI: 10.2147/CLEP.S393118] [Reference Citation Analysis]
15 Ezhilarasan D, Najimi M. Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver. Crit Rev Oncol Hematol 2023;182:103902. [PMID: 36621514 DOI: 10.1016/j.critrevonc.2022.103902] [Reference Citation Analysis]
16 Li J, Zhai X, Chen C, Zhang R, Huang X, Liu Y. 16S rRNA gene analysis reveals differentially abundant Actinobacteria, Firmicutes, and Proteobacteria in the tumors and adjacent healthy tissues of patients with hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2411606/v1] [Reference Citation Analysis]
17 Huang L, Sun H, Sun L, Shi K, Chen Y, Ren X, Ge Y, Jiang D, Liu X, Knoll W, Zhang Q, Wang Y. Rapid, label-free histopathological diagnosis of liver cancer based on Raman spectroscopy and deep learning. Nat Commun 2023;14:48. [PMID: 36599851 DOI: 10.1038/s41467-022-35696-2] [Reference Citation Analysis]
18 Su CC, Chen BS, Chen HH, Sung WW, Wang CC, Tsai MC. Improved Trends in the Mortality-to-Incidence Ratios for Liver Cancer in Countries with High Development Index and Health Expenditures. Healthcare (Basel) 2023;11. [PMID: 36673528 DOI: 10.3390/healthcare11020159] [Reference Citation Analysis]
19 Yamazaki K, Nishii R, Mizutani Y, Makishima H, Kaneko T, Isobe Y, Terada T, Tamura K, Imabayashi E, Tani T, Kobayashi M, Wakatsuki M, Tsuji H, Higashi T. Estimation of post-therapeutic liver reserve capacity using (99m)Tc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors. Eur J Nucl Med Mol Imaging 2023;50:581-92. [PMID: 36192469 DOI: 10.1007/s00259-022-05985-5] [Reference Citation Analysis]
20 Shan T, Ran X, Li H, Feng G, Zhang S, Zhang X, Zhang L, Lu L, An L, Fu R, Sun K, Wang S, Chen R, Li L, Chen W, Wei W, Zeng H, He J. Disparities in stage at diagnosis for liver cancer in China. Journal of the National Cancer Center 2023. [DOI: 10.1016/j.jncc.2022.12.002] [Reference Citation Analysis]
21 Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol 2023;20:37-49. [PMID: 36258033 DOI: 10.1038/s41575-022-00688-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang MD, Shen F, Zeng YY, Yang T. ASO Author Reflections: Effect of Preoperative Metabolic Syndrome for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2023;30:359-60. [PMID: 36121580 DOI: 10.1245/s10434-022-12557-2] [Reference Citation Analysis]
23 Biao Gao, Yafei Wang, Shichun Lu. Construction and validation of a novel signature based on epithelial-mesenchymal transition–related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. Funct Integr Genomics 2023;23:6. [PMID: 36536232 DOI: 10.1007/s10142-022-00933-w] [Reference Citation Analysis]
24 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2023;72:141-52. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
25 Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology 2023;77:323-38. [PMID: 35478412 DOI: 10.1002/hep.32542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
26 Gupta PP, Sadrani VJ, Gupta PP, Parab MM, Bastikar VA. Hepatitis C virus and hepatocellular carcinoma. Oncogenic Viruses 2023. [DOI: 10.1016/b978-0-12-824152-3.00003-2] [Reference Citation Analysis]
27 Zhao Y, Zhang L, Hu Q, Zhu D, Xie Z. Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma. Comput Biol Med 2023;152:106348. [PMID: 36470143 DOI: 10.1016/j.compbiomed.2022.106348] [Reference Citation Analysis]
28 Jeon SH, Lee YJ, Kim HD, Nam H, Ryoo BY, Park SH, Yoo C, Shin EC. Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. Cancer Immunol Immunother 2023;72:371-84. [PMID: 35902399 DOI: 10.1007/s00262-022-03258-6] [Reference Citation Analysis]
29 Kim CW, Lee HK, Nam MW, Choi Y, Choi KC. Overexpression of KiSS1 Induces the Proliferation of Hepatocarcinoma and Increases Metastatic Potential by Increasing Migratory Ability and Angiogenic Capacity. Mol Cells 2022;45:935-49. [PMID: 36572562 DOI: 10.14348/molcells.2022.0105] [Reference Citation Analysis]
30 Horackova K, Frankova S, Zemankova P, Nehasil P, Cerna M, Neroldova M, Otahalova B, Kral J, Hovhannisyan M, Stranecky V, Zima T, Safarikova M, Kalousova M, Consortium C, Novotny J, Sperl J, Borecka M, Jelinkova S, Vocka M, Janatova M, Kleiblova P, Kleibl Z, Jirsa M, Soukupova J. Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma. Cancers (Basel) 2022;15. [PMID: 36612198 DOI: 10.3390/cancers15010201] [Reference Citation Analysis]
31 Hu Z, Yuan Y, Hu Z, Liu Q, Fu Y, Hou J, Sun X, Li S, Duan W, Chen M. Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers. J Hepatocell Carcinoma 2022;9:1403-13. [PMID: 36600988 DOI: 10.2147/JHC.S390858] [Reference Citation Analysis]
32 Abza GB, Ahmed JH, Yesufe AA, Seife E, Erkie M, Spriet I, Chelkeba L, Annaert P. Clinicopathological Features and Survival of Patients with Hepatocellular Carcinoma in Ethiopia: A Multicenter Study. Cancers (Basel) 2022;15. [PMID: 36612189 DOI: 10.3390/cancers15010193] [Reference Citation Analysis]
33 Zhou L, Zhang M, Chen S. Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis. Ann Hepatol 2022;28:100890. [PMID: 36574929 DOI: 10.1016/j.aohep.2022.100890] [Reference Citation Analysis]
34 Elkomos BE, Abdo M, Mamdouh R, Abdelaal A. Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis. Hepatol Int 2022. [PMID: 36564609 DOI: 10.1007/s12072-022-10435-3] [Reference Citation Analysis]
35 Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers (Basel) 2022;15. [PMID: 36612046 DOI: 10.3390/cancers15010050] [Reference Citation Analysis]
36 Li Y, Chen X, Huang H, Liao L, Chong H, Li G, Yuan T, Lu W, Deng S, Huang Q. A feedback loop between NONHSAT024276 and PTBP1 inhibits tumor progression and glycolysis in HCC by increasing the PKM1/PKM2 ratio. Cancer Sci 2022. [PMID: 36529521 DOI: 10.1111/cas.15697] [Reference Citation Analysis]
37 Thompson EA, Fowlkes NW, Jacobsen MC, Layman RR, Cressman ENK. Quantitative Dual-Energy CT Image Guidance for Thermochemical Ablation: In Vivo Results in the Rabbit VX2 Model. J Vasc Interv Radiol 2022:S1051-0443(22)01423-3. [PMID: 36539151 DOI: 10.1016/j.jvir.2022.12.026] [Reference Citation Analysis]
38 Yue X, Lu Y, Jiang Q, Dong X, Kan X, Wu J, Kong X, Han P, Yu J, Li Q. Application of Intravoxel Incoherent Motion in the Evaluation of Hepatocellular Carcinoma after Transarterial Chemoembolization. Curr Oncol 2022;29:9855-66. [PMID: 36547188 DOI: 10.3390/curroncol29120774] [Reference Citation Analysis]
39 Abd ElAziz ON, Elfiky AM, Yassin MA, Abd El-Hakam FE, Saleh EM, El-Hefnawi M, Mohamed RH. In Silico and In Vivo Evaluation of microRNA-181c-5p's Role in Hepatocellular Carcinoma. Genes (Basel) 2022;13. [PMID: 36553610 DOI: 10.3390/genes13122343] [Reference Citation Analysis]
40 Shannon AH, Ruff SM, Pawlik TM. Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. JHC 2022;Volume 9:1247-1261. [DOI: 10.2147/jhc.s383922] [Reference Citation Analysis]
41 Zhu M, Zhang J, Bian S, Zhang X, Shen Y, Ni Z, Xu S, Cheng C, Zheng W. Circadian gene CSNK1D promoted the progression of hepatocellular carcinoma by activating Wnt/β-catenin pathway via stabilizing Dishevelled Segment Polarity Protein 3. Biol Proced Online 2022;24:21. [PMID: 36460966 DOI: 10.1186/s12575-022-00183-x] [Reference Citation Analysis]
42 Feld JJ, Forns X, Dylla DE, Kumada H, de Ledinghen V, Wei L, Brown RS Jr, Flisiak R, Lampertico P, Thabut D, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Jacobson IM. Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts. J Viral Hepat 2022;29:1050-61. [PMID: 36036117 DOI: 10.1111/jvh.13738] [Reference Citation Analysis]
43 Ahn HR, Baek GO, Yoon MG, Son JA, Yoon JH, Cheong JY, Cho HJ, Kang HC, Eun JW, Kim SS. Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:158. [DOI: 10.1186/s13046-022-02365-7] [Reference Citation Analysis]
44 Sroor FM, Basyouni WM, Aly HF, Younis EA, Mahrous KF, Haroun AA. Biochemical and histopathological studies of sulfonylurea derivative as a new chemotherapeutic agent against liver cancer in free- and nano-coated forms. Appl Biol Chem 2022;65:68. [DOI: 10.1186/s13765-022-00737-3] [Reference Citation Analysis]
45 Yan M, Wu B. Hepatitis B and C mortality from 1990 to 2019 in China: a Bayesian age-period-cohort analysis. Ann Transl Med 2022;10:1384. [PMID: 36660613 DOI: 10.21037/atm-22-5676] [Reference Citation Analysis]
46 Zhang D, Feng D, Ren M, Bai Y, Liu Z, Wang H. Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation. Ann Med 2022;54:2213-21. [PMID: 35930293 DOI: 10.1080/07853890.2022.2107233] [Reference Citation Analysis]
47 Si-Cho Kim, Jiwon Kim, Da-Won Kim, Yanghee Choi, Kyunghyun Park, Eun Ju Cho, Su Jong Yu, Jeongsil Kim-Ha, Young-Joon Kim. Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples. BMB Rep 2022;55. [PMID: 36016503 DOI: 10.5483/BMBRep.2022.55.11.110] [Reference Citation Analysis]
48 Chen J, Lai L, Luo J, Wang H, Li M, Huang M. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study. BMC Cancer 2022;22:1242. [PMID: 36451104 DOI: 10.1186/s12885-022-10361-5] [Reference Citation Analysis]
49 Chen H, Shang X, Yuan H, Niu Q, Chen J, Luo S, Li W, Li X. Total flavonoids of Oldenlandia diffusa (Willd.) Roxb. suppresses the growth of hepatocellular carcinoma through endoplasmic reticulum stress-mediated autophagy and apoptosis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019670] [Reference Citation Analysis]
50 Chen L, Lin X, Lei Y, Xu X, Zhou Q, Chen Y, Liu H, Jiang J, Yang Y, Zheng F, Wu B. Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-κBp65/HK2 signalling. J Exp Clin Cancer Res 2022;41:329. [PMID: 36411480 DOI: 10.1186/s13046-022-02531-x] [Reference Citation Analysis]
51 Li N, Wu Z, Ma C. ZHX2 in health and disease. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1038890] [Reference Citation Analysis]
52 Li Y, Ou Z, Yu D, He H, Zheng L, Chen J, Chen C, Xiong H, Chen Q. The trends in death of primary liver cancer caused by specific etiologies worldwide: results from the Global Burden of Disease Study 2019 and implications for liver cancer management.. [DOI: 10.21203/rs.3.rs-2200639/v1] [Reference Citation Analysis]
53 Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond) 2023;43:75-86. [PMID: 36397729 DOI: 10.1002/cac2.12393] [Reference Citation Analysis]
54 Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, Teriaca MA, Rimassa L, Pedicini V, Poretti D, Solbiati LA, Torzilli G, Ceriani R, Lleo A, Aghemo A, Santoro A, Scorsetti M. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). Curr Oncol 2022;29:8802-13. [PMID: 36421345 DOI: 10.3390/curroncol29110692] [Reference Citation Analysis]
55 Gray S, Lamarca A, Mcnamara MG, Edeline J, Piper‐hanley K, Valle JW, Hubner RA. Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. Liver Cancer International 2022. [DOI: 10.1002/lci2.62] [Reference Citation Analysis]
56 Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [PMID: 36369487 DOI: 10.1038/s41575-022-00704-9] [Reference Citation Analysis]
57 Zhang Y, Huang H, Jin L, Lin S. Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma. Int J Mol Sci 2022;23. [PMID: 36430307 DOI: 10.3390/ijms232213834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zhang Y, Gabere M, Tylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1042250] [Reference Citation Analysis]
59 Wang Z, Ran R, Zhang S, Zhou W, Lv J, Ma C, Zhang H. The role of long non-coding RNA HCG18 in cancer. Clin Transl Oncol 2022. [DOI: 10.1007/s12094-022-02992-8] [Reference Citation Analysis]
60 Yeo SM, Oh JH, Yu HJ, Sinn DH, Hwang JH. The effect of mHealth-based exercise on Insulin Sensitivity for patients with Hepatocellular carcinoma and insulin resistance (mISH): protocol of a randomized controlled trial. Trials 2022;23:930. [DOI: 10.1186/s13063-022-06858-w] [Reference Citation Analysis]
61 Wang H, Wang Y, Lai S, Zhao L, Liu W, Liu S, Chen H, Wang J, Du G, Tang B. LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2. Cell Death Discov 2022;8:449. [DOI: 10.1038/s41420-022-01234-8] [Reference Citation Analysis]
62 Pinazo-bandera JM, García-cortés M, Segovia-zafra A, Lucena MI, Andrade RJ. Recreational Drugs and the Risk of Hepatocellular Carcinoma. Cancers 2022;14:5395. [DOI: 10.3390/cancers14215395] [Reference Citation Analysis]
63 Qu Y, Shen X, Yuan X, Lu B. FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma. Livers 2022;2:361-371. [DOI: 10.3390/livers2040027] [Reference Citation Analysis]
64 Hong M, Li J, Chen Z, Lin X, Pan J, Gong L. Global burden of major gastrointestinal cancers and its association with socioeconomics, 1990–2019. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.942035] [Reference Citation Analysis]
65 Qian L, Li H, Tu J, Zhang Y, Dai T, Sun S, Wang J, Tu C, Zheng L. NFKBIE Is a Predictive Factor of Survival and Is Correlated With Immune Infiltration, Antigen Processing, And Presentation In Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2146706/v1] [Reference Citation Analysis]
66 Thaís B Sant’Anna, Natalia M Araujo. Adeno-associated virus infection and its impact in human health: an overview. Virol J 2022;19:173. [PMID: 36316711 DOI: 10.1186/s12985-022-01900-4] [Reference Citation Analysis]
67 Li Q, Su T, Zhang X, Pan Y, Ma S, Zhang L, Zhang X, Gao X. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma. Cancer Manag Res 2022;14:3037-46. [PMID: 36275784 DOI: 10.2147/CMAR.S379911] [Reference Citation Analysis]
68 Wang Y, Huang X, Su Z, He J, Zhao N, Nie L, Tang Y, Zhao H, Nong Q. The Glu69Asp Polymorphism of EME1 Gene is Associated with an Increased Risk of Hepatocellular Carcinoma in Guangxi Population, China. Int J Gen Med 2022;15:7855-66. [PMID: 36281338 DOI: 10.2147/IJGM.S383261] [Reference Citation Analysis]
69 Rusu I, Pirlog R, Chiroi P, Nutu A, Puia VR, Fetti AC, Rusu DR, Berindan-Neagoe I, Al Hajjar N. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. Int J Mol Sci 2022;23:12370. [PMID: 36293225 DOI: 10.3390/ijms232012370] [Reference Citation Analysis]
70 Youssef SS, Youness RA, Abbas EAE, Osman NM, ELFiky A, El-Kassas M. miR-516a-3P, a potential circulating biomarker in hepatocellular carcinoma, correlated with rs738409 polymorphism in PNPLA3. Per Med 2022. [PMID: 36239555 DOI: 10.2217/pme-2022-0005] [Reference Citation Analysis]
71 Liu Z, Li M, Hutton DW, Wagner AL, Yao Y, Zhu W, Cao L, Tang S, Pan J, Wang Y, Zhao Q, Ren H, Wang Y, Wang W. Impact of the national hepatitis B immunization program in China: a modeling study. Infect Dis Poverty 2022;11:106. [PMID: 36221140 DOI: 10.1186/s40249-022-01032-5] [Reference Citation Analysis]
72 McHenry S, Zong X, Shi M, Fritz CDL, Pedersen KS, Peterson LR, Lee JK, Fields RC, Davidson NO, Cao Y. Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. Hepatol Commun 2022;6:3299-310. [PMID: 36221229 DOI: 10.1002/hep4.2073] [Reference Citation Analysis]
73 Armakolas A, Dimopoulou V, Nezos A, Stamatakis G, Samiotaki M, Panayotou G, Tampaki M, Stathaki M, Dourakis S, Koskinas J. Cellular, Molecular and Proteomic Characteristics of Early Hepatocellular Carcinoma. Curr Issues Mol Biol 2022;44:4714-34. [PMID: 36286037 DOI: 10.3390/cimb44100322] [Reference Citation Analysis]
74 Howell J, Van H, Pham M, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan G, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson AJ, Drummer HE, Anderson D. Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study. Clin Liver Dis (Hoboken) 2022;20:136-9. [PMID: 36245683 DOI: 10.1002/cld.1261] [Reference Citation Analysis]
75 Miao Y, Chen Y, Mi D. Role of gasdermin family proteins in the occurrence and progression of hepatocellular carcinoma. Heliyon 2022;8:e11035. [PMID: 36254294 DOI: 10.1016/j.heliyon.2022.e11035] [Reference Citation Analysis]
76 Li H, Zhang S, Zhu R, Zhou Z, Xia L, Lin H, Chen S. Early assessment of chemotherapeutic response in hepatocellular carcinoma based on serum surface-enhanced Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc 2022;278:121314. [PMID: 35525180 DOI: 10.1016/j.saa.2022.121314] [Reference Citation Analysis]
77 Li D, Jia AY, Zorzi J, Griffith P, Kim AK, Dao D, Anders RA, Georgiades C, Liddell RP, Hong K, Azad NS, Ho WJ, Baretti M, Christenson E, Baghdadi A, Kamel IR, Meyer J, Ghabi E, Burkhart RA, Lafaro K, He J, Shubert C, Yarchoan M. Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic. Ann Surg Open 2022;3:e207. [PMID: 36590894 DOI: 10.1097/AS9.0000000000000207] [Reference Citation Analysis]
78 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clin Gastroenterol Hepatol 2022;20:2296-2306.e6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
79 Li C, He WQ. Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory. Liver Int 2022;42:2299-316. [PMID: 35779247 DOI: 10.1111/liv.15357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Sohn W, Kang D, Kang M, Guallar E, Cho J, Paik YH. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. Clin Mol Hepatol 2022;28:851-63. [PMID: 36263667 DOI: 10.3350/cmh.2022.0037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
81 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022;77:1136-60. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
82 Samadaei M, Senfter D, Madlener S, Uranowska K, Hafner C, Trauner M, Rohr-Udilova N, Pinter M. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma. J Cell Biochem 2022;123:1663-73. [PMID: 36271841 DOI: 10.1002/jcb.30340] [Reference Citation Analysis]
83 Nguyen MH, Roberts LR, Engel-Nitz NM, Bancroft T, Ozbay AB, Singal AG. Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States. Hepatol Commun 2022;6:3443-56. [PMID: 36178256 DOI: 10.1002/hep4.2087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Xiaochun H, Feixiong P, Shengsong O, Xiaojiao W, Yuju X, Yanhua L, Schmalz G. Identification and Validation of an Inflammatory Response-Related Polygenic Risk Score as a Prognostic Marker in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/1739995] [Reference Citation Analysis]
85 Youssef SS, Abbas EAER, Elfiky AM, Seif S, Nabeel MM, Shousha HI, Abdelaziz AO. The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma. Egypt Liver Journal 2022;12:56. [DOI: 10.1186/s43066-022-00212-0] [Reference Citation Analysis]
86 Chen T. Circulating Non-Coding RNAs as Potential Diagnostic Biomarkers in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:1029-40. [PMID: 36132427 DOI: 10.2147/JHC.S380237] [Reference Citation Analysis]
87 Wang Z, Zhang Y, Zhang Q, Ao Q, Luo C, Wang B, Bai C, Ge X, Wang Y, Wang J, Qian Y, Yu H, Gu X, Kolla J. On the Core Prescriptions and Their Mechanisms of Traditional Chinese Medicine in Hepatitis B, Liver Cirrhosis, and Liver Cancer Treatment. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/5300523] [Reference Citation Analysis]
88 Wang M, Tang S, Li C, Sun L, Xu X, Liang Y, Liu F, Gu W, Wang X, Zhou Y, Lau WY, Zhang C, Yao L, Diao Y, Gu L, Shen F, Zeng Y, Yang T. Association of Concurrent Metabolic Syndrome with Long-term Oncological Prognosis Following Liver Resection for Hepatocellular Carcinoma Among Patients with Chronic Hepatitis B Virus Infection: A Multicenter Study of 1753 Patients. Ann Surg Oncol. [DOI: 10.1245/s10434-022-12529-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Udompap P, Moscoso CG, Anugwom C, Kc M, Lim N, Lake J, Hassan M. Viral Hepatitis Among African Immigrants with Hepatocellular Carcinoma in Minnesota: High Prevalence Yet Low Awareness. J Immigrant Minority Health. [DOI: 10.1007/s10903-022-01400-1] [Reference Citation Analysis]
90 Liu Y, Liu L. Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. Cancers 2022;14:4473. [DOI: 10.3390/cancers14184473] [Reference Citation Analysis]
91 Singh A, Zahid S, Noginskiy I, Pak T, Usta S, Barsoum M, Khan U. A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology 2022;29:6445-6462. [DOI: 10.3390/curroncol29090507] [Reference Citation Analysis]
92 Zou Z, Zhang ZF, Lu C, Wang H. Comparison of time trends in the incidence of primary liver cancer between China and the United States: an age-period-cohort analysis of the Global Burden of Disease 2019. Chin Med J (Engl) 2022. [PMID: 36103990 DOI: 10.1097/CM9.0000000000001980] [Reference Citation Analysis]
93 Xu F, Meng Q, Wu F, Wang Y, Yang W, Tong Y, Liu L, Chen X, Hussain T. Identification of Warning Transition Points from Hepatitis B to Hepatocellular Carcinoma Based on Mutation Accumulation for the Early Diagnosis and Potential Drug Treatment of HBV-HCC. Oxidative Medicine and Cellular Longevity 2022;2022:1-29. [DOI: 10.1155/2022/3472179] [Reference Citation Analysis]
94 Bley E, Mohan N, Jackson I, Chaisidhivej N, Jarrett S, Lo KB, Navarro V, Rossi S, Rodgers SK, Kalman RS. Follow Up Imaging in Hepatocellular Cancer Ultrasound Screening Exams with Poor Visualization Scores. J Ultrasound Med 2022. [PMID: 36063062 DOI: 10.1002/jum.16093] [Reference Citation Analysis]
95 Thomas CE, Yu YC, Luu HN, Wang R, Paragomi P, Behari J, Yuan JM. Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Cancer Med 2022. [PMID: 36052483 DOI: 10.1002/cam4.5185] [Reference Citation Analysis]
96 Campbell C, Wang T, Gillespie I, Barnes E, Matthews PC. Characterisation of chronic hepatitis B virus infection in the UK and risk factors for hepatocellular carcinoma: a large electronic health record-based retrospective cohort study in the QResearch primary care database.. [DOI: 10.1101/2022.09.01.22279481] [Reference Citation Analysis]
97 Wallace Z, Singh PK, Dorrell L. Combination strategies to durably suppress HIV-1: Soluble T cell receptors. Journal of Virus Eradication 2022;8:100082. [DOI: 10.1016/j.jve.2022.100082] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
99 Yu M, Yu M, Ji Y. Effects of sinomenine on apoptosis of human hepatoma cell line SMMC-7721 and its molecular mechanism in vitro. mat express 2022;12:1163-1173. [DOI: 10.1166/mex.2022.2265] [Reference Citation Analysis]
100 Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, Dan YY, Roberts LR, Loomba R, Huang DQ. Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. Hepatology 2022. [PMID: 36037274 DOI: 10.1002/hep.32758] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
101 Yue T, Xu M, Cai T, Zhu H, Pourkarim MR, De Clercq E, Li G. Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period. Front Public Health 2022;10:956712. [PMID: 36091549 DOI: 10.3389/fpubh.2022.956712] [Reference Citation Analysis]
102 Liu X, Xie W, Meng S, Kang X, Liu Y, Guo L, Wang C. Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma. Cells 2022;11:2654. [DOI: 10.3390/cells11172654] [Reference Citation Analysis]
103 Lwin KM, Linn YH, Dee YKS. Effects of supplement therapy on HBV-related HCC: a case report of a significant tumour regression.. [DOI: 10.21203/rs.3.rs-1977358/v1] [Reference Citation Analysis]
104 Zhang B, Bao W, Zhang S, Chen B, Zhou X, Zhao J, Shi Z, Zhang T, Chen Z, Wang L, Zheng X, Chen G, Wang Y. LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination. Cell Death Dis 2022;13:734. [PMID: 36008384 DOI: 10.1038/s41419-022-05173-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Zhang NN, Zheng J, Wu Y, Lv JY, Zhang SW, Zhang YM, Jiang WT, Song TQ, Kim V, Tohme S, Liu T, Zhang W, Gu J, Wang ZY, Suo YH, Wang S, Li W, Zhang L, Xie Y, Zhou YH, Liu JY, Qiu YB, Shen ZY, Hao JH, Geller D, Lu W. Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation. Cancer Med 2022. [PMID: 36016484 DOI: 10.1002/cam4.5063] [Reference Citation Analysis]
106 Kafeero HM, Ndagire D, Ocama P, Kato CD, Wampande E, Kajumbula H, Kudamba A, Edgar K, Katabazi FA, Ssenku JE, Sendagire H, David Patrick Kateete6, Abdul Walusansa2, Maria Magdalene Namaganda6. The wild type alleles at positions 857 and 1031 in the Tumor Necrosis Factor gene promoter are highly conserved among the low/high endemic HBV infected persons in Uganda and may not be attributable to disease burden.. [DOI: 10.21203/rs.3.rs-1985766/v1] [Reference Citation Analysis]
107 Ren X, Zhang Q, Guo W, Wang L, Wu T, Zhang W, Liu M, Kong D. Cell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors. Front Pharmacol 2022;13:944893. [DOI: 10.3389/fphar.2022.944893] [Reference Citation Analysis]
108 Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 2022. [PMID: 35989535 DOI: 10.1002/hep.32740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
109 Haque S, Bhushan Raman R, Salam M. Role of Biomarkers in Hepatocellular Carcinoma and Their Disease Progression. Liver Cancer - Genesis, Progression and Metastasis [Working Title] 2022. [DOI: 10.5772/intechopen.105856] [Reference Citation Analysis]
110 Liu Y, Liu T, Zhao X, Gao Y. New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease. Cell Mol Life Sci 2022;79:486. [PMID: 35978227 DOI: 10.1007/s00018-022-04509-6] [Reference Citation Analysis]
111 Willemssen F, de Lussanet de la Sablonière Q, Bos D, Ijzermans J, De Man R, Dwarkasing R. Potential of a Non-Contrast-Enhanced Abbreviated MRI Screening Protocol (NC-AMRI) in High-Risk Patients under Surveillance for HCC. Cancers 2022;14:3961. [DOI: 10.3390/cancers14163961] [Reference Citation Analysis]
112 Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res 2022;10:59. [PMID: 35971182 DOI: 10.1186/s40364-022-00406-z] [Reference Citation Analysis]
113 Renzulli M, Pecorelli A, Brandi N, Marasco G, Adduci F, Tovoli F, Stefanini B, Granito A, Golfieri R. Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology Insights 2022;13:275-285. [DOI: 10.3390/gastroent13030028] [Reference Citation Analysis]
114 Liang Y, Zhang Z, Zhong D, Lai C, Dai Z, Zou H, Feng T, Shang J, Shi Y, Huang X. The prognostic significance of inflammation-immunity-nutrition score on postoperative survival and recurrence in hepatocellular carcinoma patients. Front Oncol 2022;12:913731. [DOI: 10.3389/fonc.2022.913731] [Reference Citation Analysis]
115 Campbell C, Wang T, Burrow R, Mandal S, Hippisley-cox J, Barnes E, Matthews PC. Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? Wellcome Open Res 2022;7:203. [DOI: 10.12688/wellcomeopenres.17941.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Lin B, Ma Y, Wu S. Multi-Omics and Artificial Intelligence-Guided Data Integration in Chronic Liver Disease: Prospects and Challenges for Precision Medicine. OMICS: A Journal of Integrative Biology 2022;26:415-421. [DOI: 10.1089/omi.2022.0079] [Reference Citation Analysis]
117 Cao J, Xu Y, Liu X, Cai Y, Luo B. Innovative signature establishment using lymphangiogenesis-related lncRNA pairs to predict prognosis of hepatocellular carcinoma. Heliyon 2022;8:e10215. [PMID: 36033263 DOI: 10.1016/j.heliyon.2022.e10215] [Reference Citation Analysis]
118 Yin Z, Chen D, Liang S, Li X. . JHC 2022;Volume 9:929-46. [DOI: 10.2147/jhc.s357313] [Reference Citation Analysis]
119 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2022;42:2055-66. [PMID: 34780081 DOI: 10.1111/liv.15101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Auer TA, Sofue K, Ueshima E, Rauer N, Yamaguchi T, Gebauer B, Hamm B, Murakami T, Althoff C. Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. JHC 2022;Volume 9:695-705. [DOI: 10.2147/jhc.s359705] [Reference Citation Analysis]
121 Naderi M, Hosseini SM, Behnampour N, Shahramian I, Moradi A. Determining the Prevalence of Hepatitis Delta Virus, Hepatitis C Virus, and HIV Among Mothers and Infants with Hepatitis B Virus Chronic Infection. Jundishapur J Microbiol 2022;15. [DOI: 10.5812/jjm-127879] [Reference Citation Analysis]
122 Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer 2022;22:836. [PMID: 35907848 DOI: 10.1186/s12885-022-09940-3] [Reference Citation Analysis]
123 Rao Z, Li H, Yao W, Wang Q, Ma B, Xue D, Meng X. A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC. Front Oncol 2022;12:927468. [DOI: 10.3389/fonc.2022.927468] [Reference Citation Analysis]
124 Hytiroglou P, Bioulac-sage P, Theise ND, Sempoux C. Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms. Cancers 2022;14:3670. [DOI: 10.3390/cancers14153670] [Reference Citation Analysis]
125 Sakamoto Y, Shimada S, Kamiyama T, Sugiyama K, Asahi Y, Nagatsu A, Orimo T, Kakisaka T, Kamachi H, Ito YM, Taketomi A. Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection. World J Gastrointest Surg 2022; 14(7): 670-684 [DOI: 10.4240/wjgs.v14.i7.670] [Reference Citation Analysis]
126 Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N. Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. World J Hepatol 2022; 14(7): 1480-1494 [DOI: 10.4254/wjh.v14.i7.1480] [Reference Citation Analysis]
127 Huang T, Qi H, Shen L, Wu Y, Song Z, Cao F, Liu Y, Xie L, Chen S, Tang T, Li H, Zhang Y, Feng L, Zhang H, Chen J, Fan W. Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness. Int J Hyperthermia 2022;39:935-45. [PMID: 35853727 DOI: 10.1080/02656736.2022.2093413] [Reference Citation Analysis]
128 Guo J, Zhao J, Fu W, Xu Q, Huang D. Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms. Front Immunol 2022;13:918314. [DOI: 10.3389/fimmu.2022.918314] [Reference Citation Analysis]
129 Khazaaleh S, Sarmini MT, Alomari M, Al Momani L, El Kurdi B, Asfari M, Almomani Z, Romero-marrero C. Statin Use Reduces the Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis and Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.27032] [Reference Citation Analysis]
130 Howell J, Majumdar A, Fink M, Byrne M, Mccaughan G, Strasser SI, Crawford M, Hodgkinson P, Stuart KA, Tallis C, Chen J, Wigg A, Jones R, Jaques B, Jeffrey G, Adams L, Wallace MC, Gane E, Thompson A, Gow P. The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand. Transplantation Direct 2022;8:e1345. [DOI: 10.1097/txd.0000000000001345] [Reference Citation Analysis]
131 Menshikov KV, Sultanbaev AV, Musin SI, Rakhmatullina IR, Menshikova IA, Abdeev RR, Sultanbaeva NI, Popova EV, Serebrennikov GA. Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. Kreativnaâ hirurgiâ i onkologiâ 2022;12:139-150. [DOI: 10.24060/2076-3093-2022-12-2-139-150] [Reference Citation Analysis]
132 Zhang D, Feng D, He X, Zhang X, Li L, Li Z, Niu X, Zhuang Y, Liu Z, Gao X, Wang H. The Combination of AFP and “Up-To-Seven” Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients. Front Oncol 2022;12:959151. [DOI: 10.3389/fonc.2022.959151] [Reference Citation Analysis]
133 Long X, Zhang L, Wang WQ, Zhang EL, Lv X, Huang ZY. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. Onco Targets Ther 2022;15:703-16. [PMID: 35791424 DOI: 10.2147/OTT.S365652] [Reference Citation Analysis]
134 Li J, Xian L, Zheng R, Wang Y, Wan X, Liu Y. Canthaxanthin shows anti-liver aging and anti-liver fibrosis effects by down-regulating inflammation and oxidative stress in vivo and in vitro. Int Immunopharmacol 2022;110:108942. [PMID: 35810489 DOI: 10.1016/j.intimp.2022.108942] [Reference Citation Analysis]
135 Chand V, Liao X, Guzman G, Benevolenskaya E, Raychaudhuri P. Hepatocellular carcinoma evades RB1-induced senescence by activating the FOXM1-FOXO1 axis. Oncogene 2022;41:3778-90. [PMID: 35761036 DOI: 10.1038/s41388-022-02394-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Luo S, Liang C, Zhang Q, Zhang P. Iridium photosensitizer constructed liposomes with hypoxia-activated prodrug to destrust hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.07.009] [Reference Citation Analysis]
137 Chihota BV, Riebensahm C, Muula G, Sinkala E, Chilengi R, Mulenga L, Bosomprah S, Vinikoor MJ, Bolton-Moore C, Egger M, Rauch A, Berzigotti A, Wandeler G; IeDEA-southern Africa. Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. BMJ Open Gastroenterol 2022;9:e000945. [PMID: 35831020 DOI: 10.1136/bmjgast-2022-000945] [Reference Citation Analysis]
138 Liu Y, Ouyang L, Mao C, Chen Y, Li T, Liu N, Wang Z, Lai W, Zhou Y, Cao Y, Liu S, Liang Y, Wang M, Liu S, Chen L, Shi Y, Xiao D, Tao Y. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma. Oncogene 2022. [PMID: 35688944 DOI: 10.1038/s41388-022-02370-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
139 Yu XQ, Feletto E, Smith MA, Yuill S, Baade PD. Cancer Incidence in Migrants in Australia: Patterns of Three Infection-Related Cancers. Cancer Epidemiol Biomarkers Prev 2022;31:1394-401. [PMID: 35322272 DOI: 10.1158/1055-9965.EPI-21-1349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
140 Header D, Ellakany W, Ellakany A. Fecal calprotectin level as a marker of esophageal varices in Egyptian HCV cirrhotic patients. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2022.06.013] [Reference Citation Analysis]
141 Spearman CW, Dusheiko G, Jonas E, Abdo A, Afihene M, Cunha L, Desalegn H, Kassianides C, Katsidzira L, Kramvis A, Lam P, Lesi OA, Micah EA, Musabeyezu E, Ndow G, Nnabuchi CV, Ocama P, Okeke E, Rwegasha J, Shewaye AB, Some FF, Tzeuton C, Sonderup MW. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00041-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Wang Y, Li X, Yu J, Cheng Z, Hou Q, Liang P. Prognostic Nutritional Index in Hepatocellular Carcinoma Patients With Hepatitis B Following US-Guided Percutaneous Microwave Ablation: A Retrospective Study With 1,047 Patients. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.878737] [Reference Citation Analysis]
143 Adetutu Adisa R, Adegboyega Sulaimon L. Hepatocellular Carcinoma. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.105473] [Reference Citation Analysis]
144 Xie Z, Peng Z, Zou Y, Xiao H, Li B, Zhou Q, Chen S, Xu L, Shen J, Mo Y, Peng S, Kuang M, Long J, Feng ST. Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population. BMC Cancer 2022;22:709. [PMID: 35761201 DOI: 10.1186/s12885-022-09812-w] [Reference Citation Analysis]
145 Zeng S, Li SQ, Li QH. Progress in research of alcoholic liver disease. Shijie Huaren Xiaohua Zazhi 2022; 30(12): 535-540 [DOI: 10.11569/wcjd.v30.i12.535] [Reference Citation Analysis]
146 Feng H, Liu Y, Gan Y, Li M, Liu R, Liang Z, Liu L, Li L, Chen H, Li G, Tian Z, Liu X, Ma S. AdipoR1 Regulates Ionizing Radiation-Induced Ferroptosis in HCC cells through Nrf2/xCT Pathway. Oxid Med Cell Longev 2022;2022:8091464. [PMID: 35733794 DOI: 10.1155/2022/8091464] [Reference Citation Analysis]
147 Li B, Ge YZ, Yan WW, Gong B, Cao K, Zhao R, Li C, Zhang YW, Jiang YH, Zuo S. DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway. Cell Prolif 2022;:e13273. [PMID: 35748106 DOI: 10.1111/cpr.13273] [Reference Citation Analysis]
148 Ullah MA, Tabassum T, Rashid A, Islam NN, Park MN, Moin AT, Kim B. A Multi-omics Study on the Oncogenic Roles and Clinical Significance of Dynactin Family Gene (DCTN1-6) Expression in Liver Hepatocellular Carcinoma.. [DOI: 10.1101/2022.06.18.496693] [Reference Citation Analysis]
149 Lin J, Zhang H, Yu H, Bi X, Zhang W, Yin J, Zhao P, Liang X, Qu C, Wang M, Hu M, Liu K, Wang Y, Zhou Z, Wang J, Tan X, Liu W, Shao Z, Cai J, Tang W, Cao G. Epidemiological Characteristics of Primary Liver Cancer in Mainland China From 2003 to 2020: A Representative Multicenter Study. Front Oncol 2022;12:906778. [DOI: 10.3389/fonc.2022.906778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Zhuo H, Xia J, Zhang J, Tang J, Han S, Zheng Q, Zhu D, Zhang F, Xu Z, Sun D, Tan Z, Wu C. CircASPH Promotes Hepatocellular Carcinoma Progression Through Methylation and Expression of HAO2. Front Oncol 2022;12:911715. [DOI: 10.3389/fonc.2022.911715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Kale A. Hepatocellular Carcinoma: Diagnosis and Surveillance. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99839] [Reference Citation Analysis]
152 Giakoustidis A, Koffas A, Giakoustidis D, N. Papadopoulos V. Minimally Invasive Surgery for Hepatocellular Carcinoma; Latest Advances. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99840] [Reference Citation Analysis]
153 Chen J, Gao Z, Li X, Shi Y, Tang Z, Liu W, Zhang X, Huang A, Luo X, Gao Q, Ding G, Song K, Zhou J, Fan J, Fu X, Ding Z. SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial-mesenchymal transition and mitochondrial function maintenance. Cancer Med 2023;12:459-71. [PMID: 35676831 DOI: 10.1002/cam4.4908] [Reference Citation Analysis]
154 Xing QQ, Li JM, Dong X, Zeng DY, Chen ZJ, Lin XY, Pan JS. Socioeconomics and attributable etiology of primary liver cancer, 1990-2019. World J Gastroenterol 2022; 28(21): 2361-2382 [DOI: 10.3748/wjg.v28.i21.2361] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
155 Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. JHC 2022;Volume 9:477-96. [DOI: 10.2147/jhc.s344559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 Peng F, Yuan H, Zhou Y, Wu S, Long Z, Peng Y. Diagnostic Value of Combined Detection via Protein Induced by Vitamin K Absence or Antagonist II, Alpha-Fetoprotein, and D-Dimer in Hepatitis B Virus-Related Hepatocellular Carcinoma. IJGM 2022;Volume 15:5763-73. [DOI: 10.2147/ijgm.s362359] [Reference Citation Analysis]
157 Header D, Ellakany W, Ellakany A. El nivel de calprotectina fecal como marcador de várices esofágicas en pacientes egipcios cirróticos por VHC. Revista de Gastroenterología de México 2022. [DOI: 10.1016/j.rgmx.2021.11.009] [Reference Citation Analysis]
158 Ayoub WS, Jones PD, Yang JD, Martin P. Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2022. [PMID: 35642526 DOI: 10.1080/14728214.2022.2083107] [Reference Citation Analysis]
159 Weng X, Song X, Shao R, Liu F, Liu Y. Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice. Aging and Cancer 2022;3:95-104. [DOI: 10.1002/aac2.12054] [Reference Citation Analysis]
160 Huang DQ, Singal AG, Kono Y, Tan DJ, El-serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.05.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
161 Louvet A, Trabut JB, Moreno C, Moirand R, Aubin HJ, Ntandja Wandji LC, Nourredine M, Ningarhari M, Ganne-Carrié N, Pageaux GP, Bailly F, Boursier J, Daeppen JB, Luquiens A, Nguyen-Khac E, Anty R, Orban T, Donnadieu-Rigole H, Mallat A, Bureau C, Pariente EA, Paupard T, Benyamina A, Perney P, Mathurin P, Rolland B; for the Groupe collaboratif AFEF-SFA Maladie du foie liée à l'alcool. Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. Liver Int 2022;42:1330-43. [PMID: 35488390 DOI: 10.1111/liv.15221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
162 Canillas L, Parcerisa M, Coll S, García-retortillo M, Macià F, Bessa X, Castells X, Puigvehí M, Posso M. Prevalence and characteristics of hepatitis C virus-related hepatocellular carcinoma in a Spanish university hospital. Cancer Epidemiology 2022;78:102142. [DOI: 10.1016/j.canep.2022.102142] [Reference Citation Analysis]
163 Prieto Ortíz JE, Garzón Orjuela N, Sanchez Pardo S, Prieto Ortíz RG, Eslava Schmalbach JH. Hepatocarcinoma: experiencia de la vida real en un centro especializado de Bogotá, Colombia. Rev colomb Gastroenterol 2022;37:163-173. [DOI: 10.22516/25007440.823] [Reference Citation Analysis]
164 Polanco PM, Ju MR, Chansard M, Mathew Augustine M, Meier J, Mortensen E, Zeh HJ, Yopp AC. Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11897-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
165 Zhang R, Zhong L, Sun K, Liu J, Wang Q, Mao D, Fang G, Long F, Liu J. A Study on Curcumol Influencing Proliferation and Apoptosis of Hepatocellular Carcinoma Cells through DJ-1/PTEN/PI3K/AKT Pathway. BioMed Research International 2022;2022:1-7. [DOI: 10.1155/2022/9912776] [Reference Citation Analysis]
166 Goswami R, Pavon CG, Miller IG, Berendam SJ, Williams CA, Rosenthal D, Gross M, Phan C, Byrd A, Pollara J, Permar SR, Fouda GG. Prenatal Immunization to Prevent Viral Disease Outcomes During Pregnancy and Early Life. Front Virol 2022;2. [DOI: 10.3389/fviro.2022.849995] [Reference Citation Analysis]
167 Demarchi LHF, Bandeira LM, Taira DL, Zardin MCSU, Ibanhes ML, Esposito AOP, De Arruda LDC, Gonçalves CCM, Weis-torres SMDS, Cesar GA, Da Cunha RV, Tanaka TSO, Puga MAM, De Rezende GR, Lopes RB, Uehara SNDO, Pinho JRR, Carrilho FJ, Gomes-gouvêa MS, Motta-castro ARC. Hepatitis B Virus Infection among Japanese Immigrants and Descendants: The Need to Strengthen Preventive and Control Measures. Viruses 2022;14:1085. [DOI: 10.3390/v14051085] [Reference Citation Analysis]
168 Flores JE, Thompson AJ, Ryan M, Howell J. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines 2022;10:793. [DOI: 10.3390/vaccines10050793] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
169 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Cui H, Rong W, Ma J, Zhu Q, Jiang B, Zhang L, Li C, Zhuo Z, Chen M. DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma. Gene 2022;822:146353. [PMID: 35189250 DOI: 10.1016/j.gene.2022.146353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Hu R, Li H, Horng H, Thomasian NM, Jiao Z, Zhu C, Zou B, Bai HX. Automated machine learning for differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma on multiphasic MRI. Sci Rep 2022;12:7924. [PMID: 35562532 DOI: 10.1038/s41598-022-11997-w] [Reference Citation Analysis]
172 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.3] [Reference Citation Analysis]
173 Falette Puisieux M, Pellat A, Assaf A, Ginestet C, Brezault C, Dhooge M, Soyer P, Coriat R. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers (Basel) 2022;14:2357. [PMID: 35625962 DOI: 10.3390/cancers14102357] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
174 Korsic S, Levasic N, Dezman R, Zupan LAL, Trotovsek B, Jansa R, Smid A, Popovic P. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma. Radiol Oncol 2022. [PMID: 35535426 DOI: 10.2478/raon-2022-0019] [Reference Citation Analysis]
175 Chang T, Hsu N, Chen S, Hsu I, Lee M, Lu S. Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study. Viruses 2022;14:984. [DOI: 10.3390/v14050984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Bourayou E, Golub R. Signaling Pathways Tuning Innate Lymphoid Cell Response to Hepatocellular Carcinoma. Front Immunol 2022;13:846923. [PMID: 35281021 DOI: 10.3389/fimmu.2022.846923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Nanwa N, Kwong JC, Feld JJ, Fangyun Wu C, Sander B. The mean attributable health care costs associated with hepatitis B virus in Ontario, Canada: A matched cohort study. CanLivJ. [DOI: 10.3138/canlivj-2021-0029] [Reference Citation Analysis]
178 Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:1289-99. [PMID: 34778999 DOI: 10.1002/hep.32240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
179 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Sun M, Liu X, Wei W, Ge N, Luo S, Shen S, Ge R. BAP31 Promotes Proliferation, Invasion, and Metastasis of Liver Cancer Cells via Activating PI3K/AKT Pathway. J Healthc Eng 2022;2022:7686728. [PMID: 35449837 DOI: 10.1155/2022/7686728] [Reference Citation Analysis]
181 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.2] [Reference Citation Analysis]
182 Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
183 Lee T, Rawding PA, Bu J, Hyun S, Rou W, Jeon H, Kim S, Lee B, Kubiatowicz LJ, Kim D, Hong S, Eun H. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14:2061. [PMID: 35565192 DOI: 10.3390/cancers14092061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
184 Nankya-Mutyoba J, Ejalu D, Wandera C, Beyagira R, Amandua J, Seremba E, Mugagga K, Kambugu A, Muganzi A, Easterbrook P, Ocama P. A training for health care workers to integrate hepatitis B care and treatment into routine HIV care in a high HBV burden, poorly resourced region of Uganda: the '2for1' project. BMC Med Educ 2022;22:297. [PMID: 35443646 DOI: 10.1186/s12909-022-03329-3] [Reference Citation Analysis]
185 Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022:S0929-6646(22)00144-9. [PMID: 35450743 DOI: 10.1016/j.jfma.2022.04.001] [Reference Citation Analysis]
186 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med 2022. [PMID: 35441477 DOI: 10.1002/cam4.4763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
187 Ibrahim S, Fahim SA, Tadros SA, Badary OA. Suppressive effects of thymoquinone on the initiation stage of diethylnitrosamine hepatocarcinogenesis in rats. J Biochem Mol Toxicol 2022;:e23078. [PMID: 35437842 DOI: 10.1002/jbt.23078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Way GW, Jackson KG, Muscu SR, Zhou H. Key Signaling in Alcohol-Associated Liver Disease: The Role of Bile Acids. Cells 2022;11:1374. [PMID: 35456053 DOI: 10.3390/cells11081374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
189 Abdel-Moety A, Baddour N, Salem P, Rady A, El-Shendidi A. ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation. Clin Exp Hepatol 2022;8:49-59. [PMID: 35415261 DOI: 10.5114/ceh.2022.114172] [Reference Citation Analysis]
190 Firoz A, Ali HM, Rehman S, Rather IA. Gastric Cancer and Viruses: A Fine Line between Friend or Foe. Vaccines 2022;10:600. [DOI: 10.3390/vaccines10040600] [Reference Citation Analysis]
191 Campbell C, Wang T, Burrow R, Mandal S, Hippisley-cox J, Barnes E, Matthews PC. Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?. [DOI: 10.1101/2022.04.12.22273568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Kafeero HM, Ndagire D, Ocama P, Kato CD, Wampande E, Kajumbula H, Kateete DP, Walusansa A, Kudamba A, Ssenku JE, Sendagire H. TREAT-B Algorithm for Treatment Eligibility Among Chronically Infected Hepatitis B Virus Persons in a Low and a High Endemic Region: A Potential Strategy Towards Virus Elimination by 2030. Front Virol 2022;2. [DOI: 10.3389/fviro.2022.754711] [Reference Citation Analysis]
193 Kong Y, Chen H, Chen M, Li Y, Li J, Liu Q, Xiong H, Guo T, Xie Y, Yuan Y, Zhang XL. Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis. Front Oncol 2022;12:855952. [PMID: 35392238 DOI: 10.3389/fonc.2022.855952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Moustafa M, Dähling K, Günther A, Riebandt L, Smit DJ, Riecken K, Schröder C, Zhuang R, Krech T, Kriegs M, Fehse B, Izbicki JR, Fischer L, Nashan B, Li J, Jücker M. Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model. Cancers 2022;14:1882. [DOI: 10.3390/cancers14081882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
195 Zhao M, Fu Y, Liu L, Hou Y, Shi M, Zhou H, Zhang G. Identification of Key Drug Targets and Molecular Mechanisms of Curcumae Rhizoma Acting on HBV-Related HCC: Weighted Correlation Network and Network Pharmacological Analyses. Evid Based Complement Alternat Med 2022;2022:5399766. [PMID: 35388301 DOI: 10.1155/2022/5399766] [Reference Citation Analysis]
196 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
197 Yu C, Lee H, Yang S, Wang S, Lin C, Hsieh Y, Chiou H. Protodioscin Induces Mitochondrial Apoptosis of Human Hepatocellular Carcinoma Cells Through Eliciting ER Stress-Mediated IP3R Targeting Mfn1/Bak Expression. JHC 2022;Volume 9:327-41. [DOI: 10.2147/jhc.s355027] [Reference Citation Analysis]
198 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiología y diagnóstico. Revista de Gastroenterología de México 2022;87:216-234. [DOI: 10.1016/j.rgmx.2021.10.002] [Reference Citation Analysis]
199 Chen X, Sun S, Lu Y, Shi X, Wang Z, Chen X, Han G, Zhao J, Gao Y, Wang X. Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis. Ann Transl Med 2022;10:434. [PMID: 35571416 DOI: 10.21037/atm-21-5391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Hu Z, Sun X, Mei J, Hu Z, Yang Z, Hou J, Fu Y, Wang X, Chen M. Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients. JHC 2022;Volume 9:315-25. [DOI: 10.2147/jhc.s363123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Wang P, Zhang Y, Deng L, Qu Z, Guo P, Liu L, Yu Z, Wang P, Liu N. The function and regulation network mechanism of circRNA in liver diseases. Cancer Cell Int 2022;22:141. [PMID: 35361205 DOI: 10.1186/s12935-022-02559-1] [Reference Citation Analysis]
202 Hou J, Shi K, Liu Y, Chen J, Ran C, Wang X. Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer. Evid Based Complement Alternat Med 2022;2022:9810036. [PMID: 35341138 DOI: 10.1155/2022/9810036] [Reference Citation Analysis]
203 Zhou X, Huang JM, Li TM, Liu JQ, Wei ZL, Lan CL, Zhu GZ, Liao XW, Ye XP, Peng T. Clinical Significance and Potential Mechanisms of ATP Binding Cassette Subfamily C Genes in Hepatocellular Carcinoma. Front Genet 2022;13:805961. [PMID: 35342392 DOI: 10.3389/fgene.2022.805961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon YE, Chon HJ. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers (Basel) 2022;14:1747. [PMID: 35406518 DOI: 10.3390/cancers14071747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
205 Xie G, Zhu A, Gu X. Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition. Cancers (Basel) 2022;14:1714. [PMID: 35406486 DOI: 10.3390/cancers14071714] [Reference Citation Analysis]
206 Lin C, Kuo JC, Li D, Koenig AB, Pan A, Yan P, Bai X, Lee RJ, Ghoshal K. AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells. Front Cell Dev Biol 2022;10:853652. [DOI: 10.3389/fcell.2022.853652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Zhao Y, Kong LX, Feng FS, Yang J, Wei G. A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study. BMC Cancer 2022;22:311. [PMID: 35321670 DOI: 10.1186/s12885-022-09433-3] [Reference Citation Analysis]
208 Zhuntova GV, Azizova TV, Bannikova MV, Sychugov GV. Characteristics of malignant neoplasms of the hepatobiliary system in the cohort of occupationally-exposed workers. jour 2022;21:4-12. [DOI: 10.52420/2071-5943-2022-21-1-4-12] [Reference Citation Analysis]
209 Hu Z, Zeng H, Hou J, Wang J, Xu L, Zhang Y, Chen M, Zhou Z. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses 2022;14:656. [PMID: 35458386 DOI: 10.3390/v14040656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Zhou X, Zhang T, Sun Y, Li C, Ding X, Zhu Y, Li L, Fan Z. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma. Front Pharmacol 2022;13:764854. [PMID: 35300300 DOI: 10.3389/fphar.2022.764854] [Reference Citation Analysis]
211 Huang ZH, Lu GY, Qiu LX, Zhong GH, Huang Y, Yao XM, Liu XH, Huang SJ, Wu T, Yuan Q, Wang YB, Su YY, Zhang J, Xia NS. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer 2022;22:287. [PMID: 35300634 DOI: 10.1186/s12885-022-09413-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
212 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Müller L, Hahn F, Auer TA, Fehrenbach U, Gebauer B, Haubold J, Zensen S, Kim MS, Eisenblätter M, Diallo TD, Bettinger D, Steinle V, Chang DH, Zopfs D, Pinto Dos Santos D, Kloeckner R. Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. Front Oncol 2022;12:850454. [PMID: 35280804 DOI: 10.3389/fonc.2022.850454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
214 Luo YY, Tao KG, Lu YT, Li BB, Wu KM, Ding CH, Yan FZ, Liu Y, Lin Y, Zhang X, Zeng X. Hsa_Circ_0098181 Suppresses Hepatocellular Carcinoma by Sponging miR-18a-3p and Targeting PPARA. Front Pharmacol 2022;13:819735. [PMID: 35264957 DOI: 10.3389/fphar.2022.819735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Zhang S, Xu L, Feng J, Tan D, Zhu Y, Hou J, Li W, Lv K, Wang W, Jiang L, Jiao M, Guo H. ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. Front Genet 2022;13:842351. [DOI: 10.3389/fgene.2022.842351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
216 Cococcia S, Dutta P, Moghim M, Hogan B, Tanwar S, Marshall A, Macdonald D, Yu D, O'Beirne J, Rosenberg WM, Trembling PM. The fate of indeterminate liver lesions: What proportion are precursors of hepatocellular carcinoma? BMC Gastroenterol 2022;22:118. [PMID: 35272611 DOI: 10.1186/s12876-022-02135-x] [Reference Citation Analysis]
217 Carroll HK, Duffy AG, O'Farrelly C. Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink? Semin Liver Dis 2022. [PMID: 35263795 DOI: 10.1055/s-0042-1744143] [Reference Citation Analysis]
218 Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A, Berrevoet F, Troisi RI, Van Vlierberghe H, Defreyne L. 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology 2022;:211806. [PMID: 35258371 DOI: 10.1148/radiol.211806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
219 Takaki K, Nakano M, Fukumori K, Yano Y, Zaizen Y, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Torimura T. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. J Clin Med 2022;11:1483. [PMID: 35329809 DOI: 10.3390/jcm11061483] [Reference Citation Analysis]
220 He Y, Hu B, Zhu C, Xu W, Ge Y, Hao X, Dong B, Chen X, Dong Q, Zhou X. A Novel Multimodal Radiomics Model for Predicting Prognosis of Resected Hepatocellular Carcinoma. Front Oncol 2022;12:745258. [DOI: 10.3389/fonc.2022.745258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 El-shaarawy F, Abo Elazm MM, Mohamed RH, Radwan MI, Abo-elmatty DM, Mehanna ET. Relation of the methylation state of RUNX3 and p16 gene promoters with hepatocellular carcinoma in Egyptian patients. Egypt J Med Hum Genet 2022;23. [DOI: 10.1186/s43042-022-00256-2] [Reference Citation Analysis]
222 Boyer S, Baudoin M, Nishimwe ML, Santos M, Lemoine M, Maradan G, Sylla B, Kouanfack C, Carrieri P, Mourad A, Rouveau N, Moh R, Seydi M, Attia A, Woode ME, Lacombe K. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa. BMC Health Serv Res 2022;22. [DOI: 10.1186/s12913-021-07289-0] [Reference Citation Analysis]
223 Ballerini P, Contursi A, Bruno A, Mucci M, Tacconelli S, Patrignani P. Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. Front Pharmacol 2022;13:838079. [DOI: 10.3389/fphar.2022.838079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
224 Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, Toyoda H, Esquivel CO, Bonham CA, Nguyen MH, Huang DQ. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun 2022. [PMID: 35234371 DOI: 10.1002/hep4.1923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
225 Liu X, Gao J, Sun Y, Zhang F, Guo W, Zhang S. Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway. DDDT 2022;Volume 16:863-871. [DOI: 10.2147/dddt.s354205] [Reference Citation Analysis]
226 Zhang Y, Gabere M, Taylor M, Simoes CC, Dumbauld C, Barro O, Chamcheu JC, Post SR, Kelly TJ, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy.. [DOI: 10.1101/2022.02.25.481685] [Reference Citation Analysis]
227 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
228 Liu Z, Zhou X, Zheng P, Bu C, Yan X, Yu H, Xu Y. Clinical significance of mitogen-activated protein kinase kinase kinases in hepatitis B virus -related hepatocellular carcinoma and underlying mechanism exploration. Bioengineered 2022;13:6819-38. [PMID: 35311629 DOI: 10.1080/21655979.2022.2037224] [Reference Citation Analysis]
229 Sutton TL, Pasko J, Kelly G, Maynard E, Connelly C, Orloff S, Enestvedt CK. Intraoperative autologous transfusion and oncologic outcomes in liver transplantation for hepatocellular carcinoma: a propensity matched analysis. HPB (Oxford) 2022;24:379-85. [PMID: 34294524 DOI: 10.1016/j.hpb.2021.06.433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Kahraman E, Göker E. Anticancer effects of imidazole nucleus in hepatocellular carcinoma cell lines via the inhibition of AKT and ERK1/2 signaling pathways. Mol Biol Rep 2022. [PMID: 35226260 DOI: 10.1007/s11033-022-07273-9] [Reference Citation Analysis]
231 Nenu I, Stefanescu H, Procopet B, Sparchez Z, Minciuna I, Mocan T, Leucuta D, Morar C, Grigorescu M, Filip GA, Socaciu C. Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis. JCM 2022;11:1292. [DOI: 10.3390/jcm11051292] [Reference Citation Analysis]
232 Luo X, Ji X, Xie M, Zhang T, Wang Y, Sun M, Huang W, Xia L. Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy. Cancers (Basel) 2022;14:1165. [PMID: 35267473 DOI: 10.3390/cancers14051165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
233 Ribaldone DG, Caviglia GP, Gaia S, Rolle E, Risso A, Campion D, Brunocilla PR, Saracco GM, Carucci P. Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. Current Oncology 2022;29:1422-9. [DOI: 10.3390/curroncol29030119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
234 Wen N, Cai Y, Li F, Ye H, Tang W, Song P, Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022. [PMID: 35197399 DOI: 10.5582/bst.2022.01061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
235 Nagornykh AM, Tyumentseva MA, Tyumentsev AI, Akimkin VG. Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts. PLoS ONE 2022;17:e0264266. [DOI: 10.1371/journal.pone.0264266] [Reference Citation Analysis]
236 Kaur SP, Talat A, Karimi-Sari H, Grees A, Chen HW, Lau DTY, Catana AM. Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). J Clin Med 2022;11:1126. [PMID: 35207397 DOI: 10.3390/jcm11041126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
237 Gherman B, Hajjar NA, Tucan P, Radu C, Vaida C, Mois E, Burz A, Pisla D. Risk Assessment-Oriented Design of a Needle Insertion Robotic System for Non-Resectable Liver Tumors. Healthcare 2022;10:389. [DOI: 10.3390/healthcare10020389] [Reference Citation Analysis]
238 Brown RS Jr, Collins MA, Strasser SI, Emmett A, Topp AS, Burroughs M, Ferreira R, Feld JJ. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infect Dis Ther 2022. [PMID: 35174470 DOI: 10.1007/s40121-022-00599-8] [Reference Citation Analysis]
239 Gokcen P, Guzelbulut F, Adali G, Degirmenci Salturk AG, Ozturk O, Bahadir O, Kanatsiz E, Kiyak M, Ozdil K, Doganay HL. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment. World J Gastroenterol 2022; 28(6): 665-674 [DOI: 10.3748/wjg.v28.i6.665] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Wang X, Hu Z, Fu Y, Hou J, Li W, Zhang Y, Xu L, Zhou Q, Chen M, Zhou Z. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol. [DOI: 10.1007/s00535-022-01855-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
241 Yao J, Liang X, Liu Y, Li S, Zheng M. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study. Cancer Control 2022;29:10732748211051548. [PMID: 35147456 DOI: 10.1177/10732748211051548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
242 Lin Y, Xu J, Hong J, Si Y, He Y, Zhang J. Prognostic Impact of Surgical Margin in Hepatectomy on Patients With Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Front Surg 2022;9:810479. [DOI: 10.3389/fsurg.2022.810479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Jiang T, Huang J, Xu C, Lv Y, Lu J, Zhao Z, Yang D, Lou Z, Zhang G, Wang K. Arsenic Trioxide Cooperate Cryptotanshinone Exerts Antitumor Effect by Medicating Macrophage Polarization through Glycolysis. Journal of Immunology Research 2022;2022:1-16. [DOI: 10.1155/2022/2619781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Chen W, Zhang Q, Ding M, Yao J, Guo Y, Yan W, Yu S, Shen Q, Huang M, Zheng Y, Lin Y, Wang Y, Liu Z, Lu L. Alcohol triggered bile acid disequilibrium by suppressing BSEP to sustain hepatocellular carcinoma progression. Chem Biol Interact 2022;:109847. [PMID: 35149083 DOI: 10.1016/j.cbi.2022.109847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Leoni S, Casabianca A, Biagioni B, Serio I. Viral hepatitis: Innovations and expectations. World J Gastroenterol 2022; 28(5): 517-531 [DOI: 10.3748/wjg.v28.i5.517] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
246 Caviglia GP, Troshina G, Santaniello U, Rosati G, Bombaci F, Birolo G, Nicolosi A, Saracco GM, Ciancio A. Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers 2022;14:828. [DOI: 10.3390/cancers14030828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
247 Shigematsu Y, Kanda H, Amori G, Takahashi Y, Takazawa Y, Inamura K. Nonalcoholic non-virus-related hepatocellular carcinoma arising from nonsteatotic liver: Clinical and pathological features. Medicine (Baltimore) 2022;101:e28746. [PMID: 35119029 DOI: 10.1097/MD.0000000000028746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Lee K, Choi GH, Jang ES, Jeong SH, Kim JW. A scoring system for predicting hepatocellular carcinoma risk in alcoholic cirrhosis. Sci Rep 2022;12:1717. [PMID: 35110551 DOI: 10.1038/s41598-022-05196-w] [Reference Citation Analysis]
249 Tovoli F, Garajová I, Gelsomino F, Iavarone M, Federico P, Salati M, Corianò M, Caputo F, De Lorenzo S, Granito A, Renzulli M, Daniele B, Piscaglia F. Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials. Liver Int 2022;42:458-67. [PMID: 34826193 DOI: 10.1111/liv.15117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Groopman JD, Smith JW, Rivera-Andrade A, Alvarez CS, Kroker-Lobos MF, Egner PA, Gharzouzi E, Dean M, McGlynn KA, Ramírez-Zea M. Aflatoxin and the Etiology of Liver Cancer and Its Implications for Guatemala. World Mycotoxin J 2021;14:305-17. [PMID: 35096197 DOI: 10.3920/wmj2020.2641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
251 Aujay G, Etchegaray C, Blanc J, Lapuyade B, Papadopoulos P, Pey M, Bordenave L, Trillaud H, Saut O, Pinaquy J. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. Diagnostic and Interventional Imaging 2022. [DOI: 10.1016/j.diii.2022.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Schemmer P, Burra P, Hu RH, Hüber CM, Loinaz C, Machida K, Vogel A, Samuel D. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver Int 2022;42:288-98. [PMID: 34846790 DOI: 10.1111/liv.15124] [Reference Citation Analysis]
253 Akhtar S. Preoperative evaluation of geriatric patients undergoing liver transplantation. Curr Opin Anaesthesiol 2022;35:96-104. [PMID: 34878418 DOI: 10.1097/ACO.0000000000001084] [Reference Citation Analysis]
254 Lee YT, Sun N, Kim M, Wang JJ, Tran BV, Zhang RY, Qi D, Zhang C, Chen PJ, Sadeghi S, Finn RS, Saab S, Han SB, Busuttil RW, Pei R, Zhu Y, Tseng HR, You S, Yang JD, Agopian VG. Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. Liver Transpl 2022;28:200-14. [PMID: 34664394 DOI: 10.1002/lt.26337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.1] [Reference Citation Analysis]
256 Abdelrahim M, Victor D, Esmail A, Kodali S, Graviss EA, Nguyen DT, Moore LW, Saharia A, McMillan R, Fong JN, Uosef A, Elshawwaf M, Heyne K, Ghobrial RM. Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience. Cancers (Basel) 2022;14:650. [PMID: 35158918 DOI: 10.3390/cancers14030650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
257 Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci Rep 2022;12:1517. [PMID: 35087153 DOI: 10.1038/s41598-022-05444-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
258 Xu J, Xiao X, Yan B, Yuan Q, Dong X, Du Q, Zhang J, Shan L, Ding Z, Zhou L, Efferth T. Green tea-derived theabrownin induces cellular senescence and apoptosis of hepatocellular carcinoma through p53 signaling activation and bypassed JNK signaling suppression. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02468-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Zhang Y, Li J, Cui Q, Hu P, Hu S, Qian Y. Circular RNA hsa_circ_0006091 as a novel biomarker for hepatocellular carcinoma. Bioengineered. [DOI: 10.1080/21655979.2021.2006952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Bousali M, Karamitros T. Hepatitis B Virus Integration into Transcriptionally Active Loci and HBV-Associated Hepatocellular Carcinoma. Microorganisms 2022;10:253. [DOI: 10.3390/microorganisms10020253] [Reference Citation Analysis]
261 Yan Y, He W, Chen Y, Li Q, Pan J, Yuan Y, Zeng W, Chen D, Xing W. Comprehensive Analysis to Identify the Encoded Gens of Sodium Channels as a Prognostic Biomarker in Hepatocellular Carcinoma. Front Genet 2022;12:802067. [DOI: 10.3389/fgene.2021.802067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Krag A, Roskams T, Pinzani M, Mueller S. Diagnostic challenges in patients with alcohol-related liver disease. Z Gastroenterol 2022;60:45-57. [PMID: 35042253 DOI: 10.1055/a-1713-4372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Yao C, Ng E, Wang SX. An automated and mobile magnetoresistive biosensor system for early hepatocellular carcinoma diagnosis. Biosens Bioelectron 2022;202:113982. [PMID: 35033828 DOI: 10.1016/j.bios.2022.113982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
264 Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, Lu W, Li S, Xu H, Ouyang G. The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cancer Med 2022. [PMID: 34989144 DOI: 10.1002/cam4.4530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
265 Zhao H, Han Q, Yang A, Wang Y, Wang G, Lin A, Wang X, Yin C, Zhang J. CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV. Int J Biol Sci 2022;18:154-65. [PMID: 34975324 DOI: 10.7150/ijbs.62424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
266 Arvanitakis K, Koletsa T, Mitroulis I, Germanidis G. Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy. Cancers (Basel) 2022;14:226. [PMID: 35008390 DOI: 10.3390/cancers14010226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
267 Mao S, Lu H, Zhang Y, Yu J, Li X, Peng J, Liang Y. Evaluation of Psychosocial Pathways to Family Adaptation of Chinese Patients With Liver Cancer Using the McCubbin's Family Resilience Model. Front Psychiatry 2021;12:703137. [PMID: 34975555 DOI: 10.3389/fpsyt.2021.703137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
269 Abdel-Moety A, Baddour N, Salem P, El-Tobgy H, El-Shendidi A. SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency Ablation. J Clin Exp Hepatol 2022;12:774-84. [PMID: 35677515 DOI: 10.1016/j.jceh.2021.12.001] [Reference Citation Analysis]
270 Innes H, Johnson P, Mcdonald SA, Hamill V, Yeung A, Dillon JF, Hayes PC, Went A, Barclay ST, Fraser A, Bathgate A, Goldberg DJ, Hutchinson SJ. Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making. Gastro Hep Advances 2022;1:129-136. [DOI: 10.1016/j.gastha.2021.11.008] [Reference Citation Analysis]
271 Howell J, Samani A, Mannan B, Hajiev S, Motedayen Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therap Adv Gastroenterol 2022;15:175628482211001. [DOI: 10.1177/17562848221100106] [Reference Citation Analysis]
272 Jia W, Han Y, Mao X, Xu W, Zhang Y. Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Adv 2022;12:31068-31082. [DOI: 10.1039/d2ra05127c] [Reference Citation Analysis]
273 Boni G, Guidoccio F, Volterrani D, Mariani G. Radionuclide Therapy of Tumors of the Liver and Biliary Tract. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_51-2] [Reference Citation Analysis]
274 Ghanta MK, Hussain MF, Karnalkar A, Nagabhishek SN, Nuthalapati P, Bhaskar L. Pharmacogenomics and outcomes for hepatocellular cancer treatment. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00003-3] [Reference Citation Analysis]
275 Schnabl B, Arteel GE, Stickel F, Hengstler J, Vartak N, Ghallab A, Dooley S, Li Y, Schwabe RF. Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Z Gastroenterol 2022;60:36-44. [PMID: 35042252 DOI: 10.1055/a-1714-9330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
276 Hormati A, Hajrezaei Z, Jazi K, Aslani Kolur Z, Rezvan S, Ahmadpour S. Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide. Middle East J Dig Dis 2022;14:5-23. [PMID: 36619733 DOI: 10.34172/mejdd.2022.251] [Reference Citation Analysis]
277 Kim W. Hepatocellular Carcinoma. Sex/Gender-Specific Medicine in the Gastrointestinal Diseases 2022. [DOI: 10.1007/978-981-19-0120-1_15] [Reference Citation Analysis]
278 Wan Q, Anugwom C, Desalegn H, Debes JD. Hepatocellular carcinoma in Hepatitis B and Human Immunodeficiency Virus coinfection in Africa: a focus on surveillance. Hepatoma Res 2022;8:39. [PMID: 36277115 DOI: 10.20517/2394-5079.2022.32] [Reference Citation Analysis]
279 Kornerup LS, Jepsen P, Bartels LE, Dahlerup JF, Vilstrup H. Lower Incidence of Hepatobiliary Cancer in Helicobacter pylori-Infected Persons: A Cohort Study of 53.633 Persons. J Clin Exp Hepatol 2022;12:793-9. [PMID: 35677512 DOI: 10.1016/j.jceh.2021.11.013] [Reference Citation Analysis]
280 Li W, Wang Y, Zhou X, Pan X, Lü J, Sun H, Xie Z, Chen S, Gao X. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinoma. Journal of Ginseng Research 2022;46:167-74. [DOI: 10.1016/j.jgr.2021.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
281 Cavalcante DF, Garcia ÉM, Farias NSDO, Koizumi IK, Figueiredo GM, Sato APS. Mortality due to hepatocellular carcinoma associated with hepatitis B and C viruses in the state of São Paulo, Brazil. Rev bras epidemiol 2022;25:e220004. [DOI: 10.1590/1980-549720220004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Duffy MJ. Circulating cancer biomarkers: current status and future prospects. Cancer Biomarkers 2022. [DOI: 10.1016/b978-0-12-824302-2.00009-6] [Reference Citation Analysis]
283 Abdel-Azeez HA, Elhady HA, Fikry AA. Cartilage oligomeric matrix protein as a non-invasive biomarker for diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. Gastroenterol Hepatol Bed Bench 2022;15:139-45. [PMID: 35845304] [Reference Citation Analysis]
284 Zaidi S, Gough NR, Mishra L. Mechanisms and clinical significance of TGF-β in hepatocellular cancer progression. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.02.002] [Reference Citation Analysis]
285 Li JZH, McLeod J, Ingledew PA. Quality Analysis of Online Patient Resources for Hepatocellular Carcinoma. J Clin Gastroenterol 2022;56:64-71. [PMID: 33337639 DOI: 10.1097/MCG.0000000000001477] [Reference Citation Analysis]
286 Ibrahim AH, Shash E. General Oncology Care in Egypt. Cancer in the Arab World 2022. [DOI: 10.1007/978-981-16-7945-2_4] [Reference Citation Analysis]
287 Markakis GE, Koulouris A, Tampaki M, Cholongitas E, Deutsch M, Papatheodoridis GV, Koskinas J. The changing epidemiology of hepatocellular carcinoma in Greece. Ann Gastroenterol 2022;35:88-94. [PMID: 34987294 DOI: 10.20524/aog.2021.0680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
288 Atyah M, Zhou C, Zhou Q, Chen W, Weng J, Wang P, Shi Y, Dong Q, Ren N. The Age-Specific Features and Clinical Significance of NRF2 and MAPK10 Expression in HCC Patients. IJGM 2022;Volume 15:737-48. [DOI: 10.2147/ijgm.s351263] [Reference Citation Analysis]
289 Song L, Feng D, Tan J, Zhang H. Effects of TMEM206 on the malignant behavior of HepG2 human hepatocellular carcinoma cells. Eur J Inflamm 2022;20:1721727X2211227. [DOI: 10.1177/1721727x221122724] [Reference Citation Analysis]
290 Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, Lee AU, Chang J, Yang J. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol 2022;20:44-56.e2. [PMID: 33662596 DOI: 10.1016/j.cgh.2021.02.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
291 Bergasa NV. Tumors of the Liver. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_13] [Reference Citation Analysis]
292 Dietz CA, Wedemeyer H. Rolle der Hepatitis-B-Impfung in der Prävention des hepatozellulären Karzinoms. Onkologe 2022;28:15-22. [DOI: 10.1007/s00761-021-01036-0] [Reference Citation Analysis]
293 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]
295 Daye D, Hu EY, Glazer DI, Tuncali K, Levesque V, Shyn PB. Periprocedural factors associated with overall patient survival following percutaneous image-guided liver tumor cryoablation. Int J Hyperthermia 2022;39:34-9. [PMID: 34937523 DOI: 10.1080/02656736.2021.2013552] [Reference Citation Analysis]
296 Chen X, Lu Y, Shi X, Chen X, Rong D, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma. J Oncol 2021;2021:3002480. [PMID: 34925507 DOI: 10.1155/2021/3002480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
297 Mohamed AA, Abo-amer YE, Aalkhalegy A, Fathalla LA, Elmaghraby MB, Elhoseeny MM, Mostafa SM, El-abgeegy M, Khattab RA, El-damasy DA, Salah W, Salem AM, Elmashad WM, Elbahnasawy M, Abd-elsalam S. COL1A1 Gene Expression in Hepatitis B Virus (HBV) Related Hepatocellular Carcinoma (HCC) Egyptian's Patients. TOBIOMJ 2021;11:108-114. [DOI: 10.2174/1875318302111010108] [Reference Citation Analysis]
298 Wei Y, Song Q, Zhang F, Yuan T. Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC. Can J Gastroenterol Hepatol 2021;2021:5601678. [PMID: 34912753 DOI: 10.1155/2021/5601678] [Reference Citation Analysis]
299 Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int J Mol Sci 2021;22:13578. [PMID: 34948375 DOI: 10.3390/ijms222413578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
300 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J 2021. [PMID: 34918471 DOI: 10.1002/ueg2.12188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
301 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
302 Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918 [DOI: 10.4251/wjgo.v13.i12.1896] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
303 Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma . World J Gastrointest Oncol 2021; 13(12): 2038-2049 [DOI: 10.4251/wjgo.v13.i12.2038] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
304 Qin Z, Liu X, Li Z, Wang G, Feng Z, Liu Y, Yang H, Tan C, Zhang Z, Li K. LncRNA LINC00667 aggravates the progression of hepatocellular carcinoma by regulating androgen receptor expression as a miRNA-130a-3p sponge. Cell Death Discov 2021;7:387. [PMID: 34907204 DOI: 10.1038/s41420-021-00787-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
305 Azit NA, Sahran S, Voon Meng L, Subramaniam M, Mokhtar S, Mohammed Nawi A. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country. PLoS One 2021;16:e0260675. [PMID: 34882716 DOI: 10.1371/journal.pone.0260675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
306 Li X, Lin J, Pan Y, Cui P, Xia J. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211041425. [PMID: 34866477 DOI: 10.1177/15330338211041425] [Reference Citation Analysis]
307 Xu J, Hong J, Wang Y, Zhou L, Xu B, Si Y, He Y, Chen Y. Prognostic Influence of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies. Front Surg 2021;8:769233. [PMID: 34869566 DOI: 10.3389/fsurg.2021.769233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
308 Zhang M, Zhang Z, Imamura M, Osawa M, Teraoka Y, Piotrowski J, Ishida Y, Sozzi V, Revill PA, Saito T, Chayama K, Liang TJ. Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. J Hepatol 2021;75:1335-45. [PMID: 34363922 DOI: 10.1016/j.jhep.2021.07.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
309 Nan Y, Xu X, Gao Y, Wang R, Li W, Yang M, Liu L, Duan Z, Jia J, Wei L, Zhuang H; Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention of primary liver cancer. Hepatol Int 2021;15:1289-300. [PMID: 34846705 DOI: 10.1007/s12072-021-10259-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Osman MF, Shawali IH, Metwally LIA, Kamel AH, Ibrahim MES. CT perfusion for response evaluation after interventional ablation of hepatocellular carcinoma: a prospective study. Egypt J Radiol Nucl Med 2021;52:281. [DOI: 10.1186/s43055-021-00660-5] [Reference Citation Analysis]
311 Medhat MA, Gushken F, Khaled T, Hassan E, El-Rehim AA, Kamel S. Acute-on-chronic liver failure in Egypt: an underestimated complication of liver cirrhosis. Eur J Gastroenterol Hepatol 2021;33:e458-63. [PMID: 33741801 DOI: 10.1097/MEG.0000000000002132] [Reference Citation Analysis]
312 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021;19:2597-2605.e4. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
313 Chen YS, Yang SY, Wang PM, Wang CC, Yong CC, Chen DW, Liu YW, Chuang CH, Huang PY, Yao CC, Lin YP, Tsai MC. Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study. J Pers Med 2021;11:1261. [PMID: 34945733 DOI: 10.3390/jpm11121261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
314 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
315 Tseng GW, Lin MC, Lai SW, Peng CY, Chuang PH, Su WP, Kao JT, Lai HC. Do peripartum and postmenopausal women with primary liver cancer have a worse prognosis? A nationwide cohort in Taiwan. World J Hepatol 2021; 13(11): 1766-1776 [PMID: 34904044 DOI: 10.4254/wjh.v13.i11.1766] [Reference Citation Analysis]
316 Lim YS. Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. Korean J Gastroenterol 2021;78:284-8. [PMID: 34824186 DOI: 10.4166/kjg.2021.137] [Reference Citation Analysis]
317 Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 [PMID: 34887645 DOI: 10.3748/wjg.v27.i43.7497] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
318 Xu JH, Guan YJ, Qiu ZD, Zhang X, Zi LL, Zhou Y, Chen C, Yu J, Zhang YC, Wang WX. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma. Oxid Med Cell Longev 2021;2021:6485871. [PMID: 34795841 DOI: 10.1155/2021/6485871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
319 Mwachiro M, Topazian HM, Kayamba V, Mulima G, Ogutu E, Erkie M, Lenga G, Mutie T, Mukhwana E, Desalegn H, Berhe R, Meshesha BR, Kaimila B, Kelly P, Fleischer D, Dawsey SM, Topazian MD. Gastrointestinal endoscopy capacity in Eastern Africa. Endosc Int Open 2021;9:E1827-36. [PMID: 34790551 DOI: 10.1055/a-1551-3343] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
320 Biondetti P, Saggiante L, Ierardi AM, Iavarone M, Sangiovanni A, Pesapane F, Fumarola EM, Lampertico P, Carrafiello G. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers (Basel) 2021;13:5797. [PMID: 34830949 DOI: 10.3390/cancers13225797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
321 Kitsou K, Iliopoulou M, Spoulou V, Lagiou P, Magiorkinis G. Viral Causality of Human Cancer and Potential Roles of Human Endogenous Retroviruses in the Multi-Omics Era: An Evolutionary Epidemiology Review. Front Oncol 2021;11:687631. [PMID: 34778024 DOI: 10.3389/fonc.2021.687631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
322 Ronnebaum S, Aly A, Patel D, Benavente F, Rueda JD. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepat Oncol 2022;9:HEP41. [PMID: 34765109 DOI: 10.2217/hep-2021-0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
323 Sonntag R, Penners C, Kohlhepp M, Haas U, Lambertz D, Kroh A, Cramer T, Ticconi F, Costa IG, Tacke F, Gassler N, Trautwein C, Liedtke C. Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention during Tumour Progression. Cancers (Basel) 2021;13:5680. [PMID: 34830835 DOI: 10.3390/cancers13225680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Wang H, Yang B, Cai X, Cheng X, Shen N, Liu L, Li J, Wang Y, He H, Ying P, Li B, Lu Z, Yang N, Wang X, Zhang F, Li Y, Wang W, Ning C, Zhu Y, Chang J, Miao X, Tian J, Zhong R. Hepatocellular carcinoma risk variant modulates lncRNA HLA-DQB1-AS1 expression via a long-range enhancer-promoter interaction. Carcinogenesis 2021;42:1347-56. [PMID: 34665859 DOI: 10.1093/carcin/bgab095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
325 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
326 Jin M, Chen Y, Hu S, Zhu M, Wang Y, Chen M, Peng Z. Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. Front Oncol 2021;11:751777. [PMID: 34745980 DOI: 10.3389/fonc.2021.751777] [Reference Citation Analysis]
327 Wang K, Xia Y, Zhu Y, Yu W, Guo Y, Liu L. Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. J Immunother Cancer 2021;9:e003195. [DOI: 10.1136/jitc-2021-003195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
328 Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines 2021;9:1639. [PMID: 34829868 DOI: 10.3390/biomedicines9111639] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
329 Chen Q, Chen AZ, Jia G, Li J, Zheng C, Chen K. Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma. Hepatol Commun 2021. [PMID: 34738743 DOI: 10.1002/hep4.1850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
330 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
331 Choi WM, Kim HJ, Jo AJ, Choi SH, Han S, Ko MJ, Lim YS. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver Int 2021;41:2777-85. [PMID: 34242482 DOI: 10.1111/liv.15011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
332 Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, Cheung RC, Nguyen MH. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1100-9. [PMID: 34469587 DOI: 10.1111/apt.16595] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
333 Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1134-49. [PMID: 34587302 DOI: 10.1111/apt.16611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
334 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
335 Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
336 Du N, Ma J, Zhang Z, Zhou Y, Yang M, Zhang W, Luo J, Yan Z. Development of a Novel Endovascular Brachytherapy Stent: A Proof-of-concept Study. J Clin Transl Hepatol 2021;9:711-8. [PMID: 34722186 DOI: 10.14218/JCTH.2020.00128] [Reference Citation Analysis]
337 Islam R, Mahbub F, Al-nahiun SAK, Rabbi MIH. Design and Performance Analysis of Monopole Antenna for the Detection of Early-Stage Hepatocellular Carcinoma (HCC) in Human Liver. 2021 IEEE 12th Annual Information Technology, Electronics and Mobile Communication Conference (IEMCON) 2021. [DOI: 10.1109/iemcon53756.2021.9623174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
338 Popa A, Lupulescu P, Iacob N, Sirli R. Dual Cancer in a Patient with Type 1 Gaucher Disease: Case Report and Literature Review. Timisoara Med 2021;2021:1. [DOI: 10.35995/tmj20210202] [Reference Citation Analysis]
339 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
340 Zaizen Y, Nakano M, Fukumori K, Yano Y, Takaki K, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Kuromatsu R, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T. Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:5282. [PMID: 34771452 DOI: 10.3390/cancers13215282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
341 Shayeb AE, Deghedy A, Bedewy ES, Badawy S, Abdeen N. Serum Beclin 1 and autophagy-related protein-5 and the risk of hepatocellular carcinoma among cirrhotic hepatitis C patients. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00149-w] [Reference Citation Analysis]
342 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
343 Sadiq AM, Mjemmas MG, Sadiq AM, Nkya GZ. Sarcomatoid hepatocellular carcinoma in a young African female. SAGE Open Med Case Rep 2021;9:2050313X211052452. [PMID: 34646567 DOI: 10.1177/2050313X211052452] [Reference Citation Analysis]
344 Celsa C, Giuffrida P, Giacchetto CM, Stornello C, Rancatore G, Grova M, Ricciardi MR, Rizzo S, Cammà C, Cabibbo G. Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International 2021;2:82-95. [DOI: 10.1002/lci2.38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
345 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
346 Zhang QW, Wang JY, Qiao XF, Li TL, Li X. Variations in disease burden of laryngeal cancer attributable to alcohol use and smoking in 204 countries or territories, 1990-2019. BMC Cancer 2021;21:1082. [PMID: 34620148 DOI: 10.1186/s12885-021-08814-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
347 Yu SCH, Hui JWY, Chong CCN, Cho CCM, Cheung S, Wong J, Lee KF. Comparison of Survival Outcomes in Transarterial Ethanol Ablation and Liver Resection for Solitary Hepatocellular Carcinoma ≤ 5 cm in Patients Stratified by Liver Function. Cardiovasc Intervent Radiol 2021. [PMID: 34609579 DOI: 10.1007/s00270-021-02768-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
348 Dantas E, Matos D, Coelho M, Sequeira C, Cardoso C, Oliveira AP. Hepatocellular Carcinoma with Atrial Extension: A Case Report. GE Port J Gastroenterol 2021;28:360-3. [PMID: 34604468 DOI: 10.1159/000511643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
349 Jin Y, Zhang Y, Luo X. circRNA_PTPRA functions as a sponge of miR-582-3p to regulate hepatocellular carcinoma cell proliferation, migration, invasion and apoptosis. Exp Ther Med 2021;22:1276. [PMID: 34594413 DOI: 10.3892/etm.2021.10711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
350 Niño-Ramírez S, Jaramillo-Arroyave D, Ardila O, Guevara-Casallas LG. Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. Rev Gastroenterol Mex (Engl Ed) 2021;86:356-62. [PMID: 34419411 DOI: 10.1016/j.rgmxen.2021.08.010] [Reference Citation Analysis]
351 Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China. J Clin Lab Anal 2021;35:e24013. [PMID: 34590755 DOI: 10.1002/jcla.24013] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
352 Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. J Hepatol 2021;75:795-809. [PMID: 34081959 DOI: 10.1016/j.jhep.2021.05.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
353 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
354 Cantaloube M, Castan F, Creoff M, Prunaretty J, Bordeau K, Michalet M, Assenat E, Guiu B, Pageaux GP, Ychou M, Aillères N, Fenoglietto P, Azria D, Riou O. Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4853. [PMID: 34638336 DOI: 10.3390/cancers13194853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
355 Salman A, Aon M, Hussein A, Salman M, Tourky M, Mahmoud A, Aljarad F, Elkaseer M, Shaaban HE, Moustafa A, El-Mikkawy A, Gaballa N, Abdallah H, Zaky Rashed ZF, Elkassar H. Impact of Hypothyroidism on Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. Int J Gen Med 2021;14:5711-8. [PMID: 34557025 DOI: 10.2147/IJGM.S326315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
356 Chen J, Wang J, Xie F. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis. Medicine (Baltimore) 2021;100:e27013. [PMID: 34559096 DOI: 10.1097/MD.0000000000027013] [Reference Citation Analysis]
357 Meng L, Xu KX, Zhao MX, Li K, Zhu K, Yuan DW, Wang HN, Dai PG, Yan R. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2611-8. [PMID: 34561331 DOI: 10.1097/CM9.0000000000001655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
358 Jaquet A, Muula G, Ekouevi DK, Wandeler G. Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. Curr Epidemiol Rep 2021;8:89-96. [PMID: 34532216 DOI: 10.1007/s40471-021-00273-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
359 Zhang L, Wang Z, Li M, Sun P, Bai T, Wang W, Bai H, Gou J, Wang Z. HCG18 Participates in Vascular Invasion of Hepatocellular Carcinoma by Regulating Macrophages and Tumor Stem Cells. Front Cell Dev Biol 2021;9:707073. [PMID: 34527669 DOI: 10.3389/fcell.2021.707073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
360 Ganne-Carrié N, Nahon P, Chaffaut C, N'Kontchou G, Layese R, Audureau E, Chevret S; CIRRAL group., ANRS CO12 CirVir group. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. JHEP Rep 2021;3:100285. [PMID: 34522876 DOI: 10.1016/j.jhepr.2021.100285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
361 Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
362 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
363 Dai T, Ye L, Yu H, Li K, Li J, Liu R, Lu X, Deng M, Li R, Liu W, Yang Y, Wang G. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:997-1021. [PMID: 34513744 DOI: 10.2147/JHC.S323743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Tian S, Li J, Guo Y, Dong W, Zheng X. Expression Status and Prognostic Significance of Gamma-Glutamyl Transpeptidase Family Genes in Hepatocellular Carcinoma. Front Oncol 2021;11:731144. [PMID: 34513707 DOI: 10.3389/fonc.2021.731144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Park JS, Ma H, Roh YS. Ubiquitin pathways regulate the pathogenesis of chronic liver disease. Biochem Pharmacol 2021;193:114764. [PMID: 34529948 DOI: 10.1016/j.bcp.2021.114764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Liu Y, Li YQ, Huang SH, Li YL, Xia JW, Jia JS, Wei F, Wang JH, Dai GQ, Wang YC, Li XY, Han LX, Zhang XL, Xiang XD, Zhao WT, Xiao D, Lin XL. Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways. Aging (Albany NY) 2021;13:21155-90. [PMID: 34517344 DOI: 10.18632/aging.203402] [Reference Citation Analysis]
367 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Kim KW, Choi JI. Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1665. [PMID: 34574006 DOI: 10.3390/diagnostics11091665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
368 Pohl K, Moodley P, Dhanda AD. Alcohol's Impact on the Gut and Liver. Nutrients 2021;13:3170. [PMID: 34579046 DOI: 10.3390/nu13093170] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
369 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
370 Liu Q, Gao P, Li Q, Xu C, Qu K, Zhang J. Long non-coding RNA SNHG16 as a potential biomarker in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e27178. [PMID: 34516515 DOI: 10.1097/MD.0000000000027178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
371 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
372 Liu L, Wang Y, Zhang J, Wang C, Li Y, Dai W, Piao C, Liu J, Yu H, Li X, Wang Y, Liu J. Probiotics in treating with alcoholic liver disease and nonalcoholic fatty liver disease. Food Reviews International. [DOI: 10.1080/87559129.2021.1967380] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
373 Guo C, Zou X, Hong Z, Sun J, Xiao W, Sun K, Li X, Shen Y, Liang T, Bai X. Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. HPB (Oxford) 2021;23:1427-38. [PMID: 33715958 DOI: 10.1016/j.hpb.2021.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Chen Y, Yang L, Millwood IY, Walters RG, Wang S, Chen J, Chen Z, Li L. Metabolic risk factors, genetic predisposition, and risk of severe liver disease in Chinese: a prospective study of 0.5 million people. Am J Clin Nutr 2021;114:496-504. [PMID: 33964851 DOI: 10.1093/ajcn/nqab099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
375 Iwata H, Ogino H, Hattori Y, Nakajima K, Nomura K, Hashimoto S, Hayashi K, Toshito T, Sasaki S, Mizoe JE, Shibamoto Y. A Phase 2 Study of Image-Guided Proton Therapy for Operable or Ablation-Treatable Primary Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2021;111:117-26. [PMID: 33798564 DOI: 10.1016/j.ijrobp.2021.03.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
376 Sutton TL, Billingsley KG, Walker BS, Fung AW, Maynard E, Enestvedt CK, Dewey EN, Brinkerhoff BT, Lopez CD, Orloff SL, Mayo SC. Detection of Tumor Multifocality in Resectable Intrahepatic Cholangiocarcinoma: Defining the Optimal Pre-operative Imaging Modality. J Gastrointest Surg 2021;25:2250-7. [PMID: 33565011 DOI: 10.1007/s11605-021-04911-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
377 Yu Z, Song Y, Cai M, Jiang B, Zhang Z, Wang L, Jiang Y, Zou L, Liu X, Yu N, Mao X, Peng C, Liu S. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:21294-308. [PMID: 34470916 DOI: 10.18632/aging.203459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
378 Cao M, Ding C, Xia C, Li H, Sun D, He S, Chen W. Attributable deaths of liver cancer in China. Chin J Cancer Res 2021;33:480-9. [PMID: 34584373 DOI: 10.21147/j.issn.1000-9604.2021.04.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
379 Samant H, Kohli K, Patel K, Shi R, Jordan P, Morris J, Schwartz A, Alexander JS. Clinical Presentation of Hepatocellular Carcinoma in African Americans vs. Caucasians: A Retrospective Analysis. Pathophysiology 2021;28:387-99. [PMID: 35366282 DOI: 10.3390/pathophysiology28030026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
380 Zhao T, Guo BJ, Xiao CL, Chen JJ, Lü C, Fang FF, Li B. Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. J Integr Med 2021;19:418-27. [PMID: 34454893 DOI: 10.1016/j.joim.2021.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
381 Centonze L, Di Sandro S, Lauterio A, De Carlis R, Sgrazzutti C, Ciulli C, Vella I, Vicentin I, Incarbone N, Bagnardi V, Vanzulli A, De Carlis L. A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: every nodule matters. Transpl Int 2021;34:1712-21. [PMID: 34448275 DOI: 10.1111/tri.13983] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
382 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 2021;12:S361-73. [PMID: 34422400 DOI: 10.21037/jgo.2020.02.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
383 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
384 Huang J, Lok V, Ngai CH, Chu C, Patel HK, Thoguluva Chandraseka V, Zhang L, Chen P, Wang S, Lao XQ, Tse LA, Xu W, Zheng ZJ, Wong MCS. Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis. Liver Cancer 2021;10:330-45. [PMID: 34414121 DOI: 10.1159/000515304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
385 Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Front Oncol 2021;11:650394. [PMID: 34408974 DOI: 10.3389/fonc.2021.650394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
386 Carbone A, De Santis E, Cela O, Giambra V, Miele L, Marrone G, Grieco A, Buschbeck M, Capitanio N, Mazza T, Mazzoccoli G. The Histone Variant MacroH2A1 Impacts Circadian Gene Expression and Cell Phenotype in an In Vitro Model of Hepatocellular Carcinoma. Biomedicines 2021;9:1057. [PMID: 34440260 DOI: 10.3390/biomedicines9081057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
387 He F, Sha Y, Wang B. Relationship between alcohol consumption and the risks of liver cancer, esophageal cancer, and gastric cancer in China: Meta-analysis based on case-control studies. Medicine (Baltimore) 2021;100:e26982. [PMID: 34414976 DOI: 10.1097/MD.0000000000026982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
388 Lin HD, Tseng YK, Yuh CH, Chen SC. Low concentrations of 4-ABP promote liver carcinogenesis in human liver cells and a zebrafish model. J Hazard Mater 2021;423:126954. [PMID: 34474361 DOI: 10.1016/j.jhazmat.2021.126954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
389 Fang C, Li W, Yin R, Zhu D, Liu X, Wu H, Wang Q, Wang W, Bai Q, Chen B, Yao X, Chen Y. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway. Sci Rep 2021;11:16507. [PMID: 34389740 DOI: 10.1038/s41598-021-93055-5] [Reference Citation Analysis]
390 Liang BY, Gu J, Xiong M, Zhang EL, Zhang ZY, Chen XP, Huang ZY. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. Sci Rep 2021;11:16343. [PMID: 34381132 DOI: 10.1038/s41598-021-95835-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
391 Marini TJ, Oppenheimer DC, Baran TM, Rubens DJ, Dozier A, Garra B, Egoavil MS, Quinn RA, Kan J, Ortega RL, Zhao YT, Tamayo L, Carlotto C, Castaneda B. Testing telediagnostic right upper quadrant abdominal ultrasound in Peru: A new horizon in expanding access to imaging in rural and underserved areas. PLoS One 2021;16:e0255919. [PMID: 34379679 DOI: 10.1371/journal.pone.0255919] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
392 Yang CJ, Wang CK, Fang YD, Wang JY, Su FC, Tsai HM, Lin YJ, Tsai HW, Yeh LR. Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets. PLoS One 2021;16:e0255605. [PMID: 34375365 DOI: 10.1371/journal.pone.0255605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
393 Qiu R, Murata S, Cheng C, Mori A, Nie Y, Mikami S, Hasegawa S, Tadokoro T, Okamoto S, Taniguchi H. A Novel Orthotopic Liver Cancer Model for Creating a Human-like Tumor Microenvironment. Cancers (Basel) 2021;13:3997. [PMID: 34439154 DOI: 10.3390/cancers13163997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
394 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
395 Li C, He WQ. The impact of universal hepatitis B vaccine on the trend of liver cancer from the Global Burden of Disease Study 2017. Liver Int 2021;41:1762-74. [PMID: 33590659 DOI: 10.1111/liv.14821] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
396 Wong YJ, Qiu TY, Ng GK, Zheng Q, Teo EK. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:615-23. [PMID: 33606427 DOI: 10.1097/MCG.0000000000001478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
397 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
398 Driedger M, Vachon M, Wong A, Conway B, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld J, Lee SS, Cooper C. Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis. CanLivJ 2021;4:283-91. [DOI: 10.3138/canlivj-2021-0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E, Roviello G. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34289756 DOI: 10.1080/17512433.2021.1958674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
400 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
401 Zhou Y, Tao J, Calvisi DF, Chen X. Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Semin Liver Dis 2021. [PMID: 34311471 DOI: 10.1055/s-0041-1731709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
402 Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J 2021;62:758-66. [PMID: 34296554 DOI: 10.3349/ymj.2021.62.8.758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
403 Zhang YW, Chen Q, Li B, Li HY, Zhao XK, Xiao YY, Liu S, Zuo S. NAP1L1 Functions as a Tumor Promoter via Recruiting Hepatoma-Derived Growth Factor/c-Jun Signal in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:659680. [PMID: 34368121 DOI: 10.3389/fcell.2021.659680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
404 Dawood AA, Saleh AA, Elbahr O, Gohar SF, Habieb MS. Inverse relationship between the level of miRNA 148a-3p and both TGF-β1 and FIB-4 in hepatocellular carcinoma. Biochem Biophys Rep 2021;27:101082. [PMID: 34355070 DOI: 10.1016/j.bbrep.2021.101082] [Reference Citation Analysis]
405 So R, Chen J, Mehta AJ, Liu S, Strak M, Wolf K, Hvidtfeldt UA, Rodopoulou S, Stafoggia M, Klompmaker JO, Samoli E, Raaschou-Nielsen O, Atkinson R, Bauwelinck M, Bellander T, Boutron-Ruault MC, Brandt J, Brunekreef B, Cesaroni G, Concin H, Forastiere F, van Gils CH, Gulliver J, Hertel O, Hoffmann B, de Hoogh K, Janssen N, Lim YH, Westendorp R, Jørgensen JT, Katsouyanni K, Ketzel M, Lager A, Lang A, Ljungman PL, Magnusson PKE, Nagel G, Simonsen MK, Pershagen G, Peter RS, Peters A, Renzi M, Rizzuto D, Sigsgaard T, Vienneau D, Weinmayr G, Severi G, Fecht D, Tjønneland A, Leander K, Hoek G, Andersen ZJ. Long-term exposure to air pollution and liver cancer incidence in six European cohorts. Int J Cancer 2021. [PMID: 34278567 DOI: 10.1002/ijc.33743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
406 Lu F, Shah PA, Rao A, Gifford-Hollingsworth C, Chen A, Trey G, Soryal M, Talat A, Aslam A, Nasir B, Choudhry S, Ishtiaq R, Sanoff H, Conteh LF, Noonan A, Hu KQ, Schmidt C, Fu M, Civan J, Xiao G, Lau DT, Lu X. Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00271. [PMID: 33512798 DOI: 10.14309/ctg.0000000000000271] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
407 Yang X, Liu Q, Zou J, Li YK, Xie X. Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC). Cancer Manag Res 2021;13:5683-98. [PMID: 34295189 DOI: 10.2147/CMAR.S316588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
408 Barzi A, Zhou K, Wang S, Dodge JL, El-Khoueiry A, Setiawan VW. Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. Cancers (Basel) 2021;13:3476. [PMID: 34298690 DOI: 10.3390/cancers13143476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
409 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
410 Huang S, Li D, Zhuang L, Sun L, Wu J. Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:690151. [PMID: 34307456 DOI: 10.3389/fmolb.2021.690151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
411 Paik JM, Mir S, Alqahtani SA, Younossi Y, Ong JP, Younossi ZM. Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. Hepatol Commun 2021. [PMID: 34558838 DOI: 10.1002/hep4.1707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
412 Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY) 2021;13:17592-606. [PMID: 34237708 DOI: 10.18632/aging.203249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
413 Hsiao CY, Yang PC, Huang KW. Linear radiofrequency ablation using dual switching-control mode achieves rapid and bloodless liver resection, an experimental research. Int J Hyperthermia 2021;38:357-62. [PMID: 33641575 DOI: 10.1080/02656736.2021.1892215] [Reference Citation Analysis]
414 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
415 Franses JW, Bhan I, Zhu AX. PLSec: A novel, liquid biomarker for HCC risk. Med 2021;2:788-90. [DOI: 10.1016/j.medj.2021.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
416 Jeong Y, Lee KJ, Lee SJ, Shin YM, Kim MJ, Lim YS, Lee HC, Jung J, Park JH, Kim JH, Kim SY, Yoon SM. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. J Gastroenterol Hepatol 2021;36:1962-70. [PMID: 33594690 DOI: 10.1111/jgh.15442] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
417 Tabu K, Mawatari S, Oda K, Taniyama O, Toyodome A, Ijuin S, Sakae H, Kumagai K, Kanmura S, Ido A. Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease. Mol Clin Oncol 2021;15:174. [PMID: 34276993 DOI: 10.3892/mco.2021.2336] [Reference Citation Analysis]
418 Lobo DA, Ginestra P, Ceretti E, Miquel TP, Ciurana J. Cancer Cell Direct Bioprinting: A Focused Review. Micromachines (Basel) 2021;12:764. [PMID: 34203530 DOI: 10.3390/mi12070764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Kang MK, Choi JH. Parenchymal Extinction Mimicking Hepatocellular Carcinoma in a Patient with Chronic Hepatitis B-Related Liver Cirrhosis. Diagnostics (Basel) 2021;11:1171. [PMID: 34203262 DOI: 10.3390/diagnostics11071171] [Reference Citation Analysis]
420 Ndow G, Cessay A, Cohen D, Shimakawa Y, Gore ML, Tamba S, Ghosh S, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, Thursz M, Chemin I, Lemoine M. Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa. J Infect Dis 2021:jiab327. [PMID: 34160616 DOI: 10.1093/infdis/jiab327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
421 Li L, Halpert G, Lerner MG, Hu H, Dimitrion P, Weiss MJ, He J, Philosophe B, Burkhart R, Burns WR, Wesson RN, MacGregor Cameron A, Wolfgang CL, Georgiades C, Kawamoto S, Azad NS, Yarchoan M, Meltzer SJ, Oshima K, Ensign LM, Bader JS, Selaru FM. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. JCI Insight 2021;6:138197. [PMID: 34003798 DOI: 10.1172/jci.insight.138197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
422 Zhong C, Liu Z, Zhang X, Pu Y, Yang Z, Bao Y. Physicochemical properties of polysaccharides from Ligusticum chuanxiong and analysis of their anti-tumor potential through immunoregulation. Food Funct 2021;12:1719-31. [PMID: 33502414 DOI: 10.1039/d0fo02978e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
423 Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Warmoes MO, Lorenzi PL, Wang Y, Wei P, Hawk ET, Almeda JL, McCormick JB, Fisher-Hoch SP, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 2021;30:1643-51. [PMID: 34155064 DOI: 10.1158/1055-9965.EPI-21-0183] [Reference Citation Analysis]
424 Dakurah OB, Tamandjou CRT, Zunza M, Preiser W, Maponga TG. Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review. BMC Cancer 2021;21:715. [PMID: 34144696 DOI: 10.1186/s12885-021-08426-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
425 Giannis D, Morsy S, Geropoulos G, Esagian SM, Sioutas GS, Moris D. The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. In Vivo 2021;35:393-9. [PMID: 33402488 DOI: 10.21873/invivo.12270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
426 Gabbia D, Cannella L, De Martin S. The Role of Oxidative Stress in NAFLD-NASH-HCC Transition-Focus on NADPH Oxidases. Biomedicines 2021;9:687. [PMID: 34204571 DOI: 10.3390/biomedicines9060687] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
427 Kukla DA, Khetani SR. Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine. Semin Liver Dis 2021;41:368-92. [PMID: 34139785 DOI: 10.1055/s-0041-1731016] [Reference Citation Analysis]
428 Hewitt DB, Rahnemai-Azar AA, Pawlik TM. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opin Investig Drugs 2021;30:827-35. [PMID: 34102935 DOI: 10.1080/13543784.2021.1940948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
429 Lin J, Zhao S, Wang D, Song Y, Che Y, Yang X, Mao J, Xie F, Long J, Bai Y, Yang X, Zhang L, Bian J, Lu X, Sang X, Pan J, Wang K, Zhao H. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. Front Immunol 2021;12:673248. [PMID: 34211467 DOI: 10.3389/fimmu.2021.673248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
430 Reimer RP, Hokamp NG, Niehoff J, Zopfs D, Lennartz S, Heidar M, Wahba R, Stippel D, Maintz D, Dos Santos DP, Wybranski C. Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. PLoS One 2021;16:e0252678. [PMID: 34129650 DOI: 10.1371/journal.pone.0252678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
431 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
432 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 58] [Article Influence: 29.0] [Reference Citation Analysis]
433 Lee HA, Goh HG, Lee YS, Jung YK, Kim JH, Yim HJ, Lee MG, An H, Jeen YT, Yeon JE, Byun KS, Seo YS. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterol 2021;21:258. [PMID: 34118869 DOI: 10.1186/s12876-021-01833-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
434 Healy K, Pavesi A, Parrot T, Sobkowiak MJ, Reinsbach SE, Davanian H, Tan AT, Aleman S, Sandberg JK, Bertoletti A, Sällberg Chen M. Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Rep 2021;3:100318. [PMID: 34377970 DOI: 10.1016/j.jhepr.2021.100318] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
435 Patel N, Maher J, Lie X, Gwaltney C, Barzi A, Karwal M, Macarulla T, Sun HC, Trojan J, Meyers O, Workman C, Morgan S, Negro A, Cohen G. Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Qual Life Res 2021. [PMID: 34115280 DOI: 10.1007/s11136-021-02903-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
436 Arvanitakis K, Mitroulis I, Germanidis G. Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. Cancers (Basel) 2021;13:2899. [PMID: 34200529 DOI: 10.3390/cancers13122899] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
437 Huang S, Li D, Zhuang L, Sun L, Wu J. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World J Surg Oncol 2021;19:168. [PMID: 34112190 DOI: 10.1186/s12957-021-02280-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
438 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol 2021;11:696183. [PMID: 34178694 DOI: 10.3389/fonc.2021.696183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
439 Zhao H, Liu S, Zhao H, Liu Y, Xue M, Zhang H, Qiu X, Sun Z, Liang H. Protective effects of fucoidan against ethanol-induced liver injury through maintaining mitochondrial function and mitophagy balance in rats. Food Funct 2021;12:3842-54. [PMID: 33977968 DOI: 10.1039/d0fo03220d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
440 Deng T, Hu B, Jin C, Tong Y, Zhao J, Shi Z, Zhang T, Deng L, Sun Z, Chen G, Wang Y. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma. J Cell Mol Med 2021;25:6618-33. [PMID: 34085405 DOI: 10.1111/jcmm.16666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
441 Abd El Aziz MA, Sacco R, Facciorusso A. Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. Antivir Chem Chemother 2020;28:2040206620921331. [PMID: 32418480 DOI: 10.1177/2040206620921331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
442 Liu Z, Xu K, Jiang Y, Cai N, Fan J, Mao X, Suo C, Jin L, Zhang T, Chen X. Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. Int J Epidemiol. 2021;50:128-142. [PMID: 33349860 DOI: 10.1093/ije/dyaa196] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
443 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
444 Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Hepatology 2021;73:2342-60. [PMID: 33140851 DOI: 10.1002/hep.31614] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
445 Zhou W, Fang D, He Y, Wei J. Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. J Gastrointest Oncol 2021;12:1117-31. [PMID: 34295561 DOI: 10.21037/jgo-21-259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
446 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
447 Opneja A, Cioffi G, Alahmadi A, Jones N, Tang TY, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Mangla A, Barnholtz-Sloan J, Lee RT. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014. Cancer Med 2021;10:4397-404. [PMID: 34060249 DOI: 10.1002/cam4.3985] [Reference Citation Analysis]
448 Moura Cunha G, Chernyak V, Fowler KJ, Sirlin CB. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:513-27. [PMID: 34104640 DOI: 10.2147/JHC.S268288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
449 Unfried JP, Sangro P, Prats-Mari L, Sangro B, Fortes P. The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers (Basel) 2021;13:2651. [PMID: 34071216 DOI: 10.3390/cancers13112651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
450 Thomas CE, Luu HN, Wang R, Xie G, Adams-Haduch J, Jin A, Koh WP, Jia W, Behari J, Yuan JM. Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancers (Basel) 2021;13:2648. [PMID: 34071196 DOI: 10.3390/cancers13112648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
451 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
452 Hatano Y, Ideta T, Hirata A, Hatano K, Tomita H, Okada H, Shimizu M, Tanaka T, Hara A. Virus-Driven Carcinogenesis. Cancers (Basel) 2021;13:2625. [PMID: 34071792 DOI: 10.3390/cancers13112625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
453 Li W, Xiao H, Wu H, Xu X, Zhang Y. Liver Transplantation Versus Liver Resection for Stage I and II Hepatocellular Carcinoma: Results of an Instrumental Variable Analysis. Front Oncol 2021;11:592835. [PMID: 34123771 DOI: 10.3389/fonc.2021.592835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
454 Bouvry C, Ardisson V, Noiret N, Garin E, Lepareur N. Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma. Processes 2021;9:940. [DOI: 10.3390/pr9060940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
455 Zhong W, Liu H, Deng L, Chen G, Liu Y. HBO1 overexpression is important for hepatocellular carcinoma cell growth. Cell Death Dis 2021;12:549. [PMID: 34039960 DOI: 10.1038/s41419-021-03818-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
456 Hu J, Zhang ZQ, Zhu W, Wu ZR, You Y, Liu Y, Su DW, Wang YB, Gong JP. Comparison of clinicopathological traits and prognostic factors of hepatocellular carcinoma with and without cirrhotic background. Carcinogenesis 2020;41:1576-82. [PMID: 32188964 DOI: 10.1093/carcin/bgaa024] [Reference Citation Analysis]
457 Liu ZL, Liu JH, Staiculescu D, Chen J. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Ther Adv Med Oncol 2021;13:17588359211018026. [PMID: 34104226 DOI: 10.1177/17588359211018026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
458 Shen Y, Xiong W, Gu Q, Zhang Q, Yue J, Liu C, Wang D. Multi-Omics Integrative Analysis Uncovers Molecular Subtypes and mRNAs as Therapeutic Targets for Liver Cancer. Front Med (Lausanne) 2021;8:654635. [PMID: 34109194 DOI: 10.3389/fmed.2021.654635] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
459 Youn SY, Kim DH, Choi JI, Choi MH, Kim B, Shin YR, Oh SN, Rha SE. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI. Korean J Radiol 2021;22:1289-99. [PMID: 34047507 DOI: 10.3348/kjr.2020.1394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
460 deLemos A, Patel M, Gawrieh S, Burney H, Dakhoul L, Miller E, Scanga A, Kettler C, Liu H, Roche P, Wattacheril J, Chalasani N. Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. Clin Transl Gastroenterol 2020;11:e00139. [PMID: 32352723 DOI: 10.14309/ctg.0000000000000139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
461 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
462 Hong YM, Yoon KT, Cho M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer 2021;21:569. [PMID: 34006248 DOI: 10.1186/s12885-021-08124-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
463 Abdulaziz BA, El Agawy W, Ibrahim ME, Khalil MA, Abdel Halim WA. Significance of Carbohydrate Antigen 19-9 as a biomarker in Hepatocellular Carcinoma and Cholangiocarcinoma. TOBIOMJ 2021;11:39-47. [DOI: 10.2174/1875318302111010039] [Reference Citation Analysis]
464 Pohlman RM, Hinshaw JL, Ziemlewicz TJ, Lubner MG, Wells SA, Lee FT Jr, Alexander ML, Wergin KL, Varghese T. Differential Imaging of Liver Tumors before and after Microwave Ablation with Electrode Displacement Elastography. Ultrasound Med Biol 2021;47:2138-56. [PMID: 34011451 DOI: 10.1016/j.ultrasmedbio.2021.03.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
465 Lee HA, Lee YS, Kim BK, Jung YK, Kim SU, Park JY, Kim JH, An H, Kim DY, Yim HJ, Ahn SH, Yeon JE, Byun KS, Han KH, Um SH, Seo YS. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut Liver 2021;15:420-9. [PMID: 32839362 DOI: 10.5009/gnl20101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
466 Zhang Y, Wang Y. Circular RNAs in Hepatocellular Carcinoma: Emerging Functions to Clinical Significances. Front Oncol 2021;11:667428. [PMID: 34055634 DOI: 10.3389/fonc.2021.667428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
467 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 13.5] [Reference Citation Analysis]
468 Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma. Microrna 2020;9:25-40. [PMID: 31218966 DOI: 10.2174/2211536608666190619155406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
469 El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev 2021;98:102221. [PMID: 34029957 DOI: 10.1016/j.ctrv.2021.102221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
470 Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep 2021;3:100304. [PMID: 34136776 DOI: 10.1016/j.jhepr.2021.100304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
471 Nie JJ, Liu Y, Qi Y, Zhang N, Yu B, Chen DF, Yang M, Xu FJ. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma. J Control Release 2021;333:362-73. [PMID: 33785418 DOI: 10.1016/j.jconrel.2021.03.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
472 Dikilitas M. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better? J Gastrointest Cancer 2020;51:1193-6. [PMID: 32869146 DOI: 10.1007/s12029-020-00497-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
473 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Artzner C, Bitzer M, Horger M, Grözinger G. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone. Eur J Radiol 2021;140:109768. [PMID: 33991970 DOI: 10.1016/j.ejrad.2021.109768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
474 Chen L, Ren Y, Sun T, Cao Y, Yan L, Zhang W, Ouyang T, Zheng C. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. Cancer Med 2021;10:3715-25. [PMID: 33960697 DOI: 10.1002/cam4.3923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
475 Shen J, Li G, Zhu Y, Xu Q, Zhou H, Xu K, Huang K, Zhan R, Pan J. Foxo1-induced miR-92b down-regulation promotes blood-brain barrier damage after ischaemic stroke by targeting NOX4. J Cell Mol Med 2021;25:5269-82. [PMID: 33955666 DOI: 10.1111/jcmm.16537] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
476 Isfordink CJ, van Erpecum KJ, van der Valk M, Mauser-Bunschoten EP, Makris M. Viral hepatitis in haemophilia: historical perspective and current management. Br J Haematol 2021. [PMID: 33955555 DOI: 10.1111/bjh.17438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
477 Vogel A, Bathon M, Saborowski A. Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Rev Anticancer Ther 2021;21:621-8. [PMID: 33499684 DOI: 10.1080/14737140.2021.1882855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
478 Liu X, Zhou P, He K, Wen Z, Gao Y. Dioscorea Zingiberensis New Saponin Inhibits the Growth of Hepatocellular Carcinoma by Suppressing the Expression of Long Non-coding RNA TCONS-00026762. Front Pharmacol 2021;12:678620. [PMID: 34012402 DOI: 10.3389/fphar.2021.678620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
479 Saberi B, Naik H, Overbey JR, Erwin AL, Anderson KE, Bissell DM, Bonkovsky HL, Phillips JD, Wang B, K Singal A, M McGuire B, Desnick RJ, Balwani M. Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology 2021;73:1736-46. [PMID: 32681675 DOI: 10.1002/hep.31460] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
480 Ueshima E, Sofue K, Murakami T. Imaging Diagnosis of HCC Featuring LI-RADS. Acta hepatologica Japonica 2021;62:229-239. [DOI: 10.2957/kanzo.62.229] [Reference Citation Analysis]
481 Desai N, Rich NE, Jain MK, Blackwell JM, Murphy CC, Perryman P, McBryde J, Quirk L, Clark C, Villarreal D, Waljee AK, Gopal P, Singal AG. Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. Am J Gastroenterol 2021;116:976-83. [PMID: 33337657 DOI: 10.14309/ajg.0000000000001085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
482 Asrani SK, Mellinger J, Arab JP, Shah VH. Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action. Hepatology 2021;73:2039-50. [PMID: 32986883 DOI: 10.1002/hep.31583] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
483 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
484 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
485 Buchanan R, Sinclair JMA. Alcohol use disorder and the liver. Addiction 2021;116:1270-8. [PMID: 32710592 DOI: 10.1111/add.15204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
486 Carr J, Cha DE, Shaltiel T, Zheng S, Siderides C, Golas B, Labow D, Magge D, Cohen N, Branch A, Sarpel U. African Immigrants in New York City with Hepatitis B-Related Hepatocellular Carcinoma Demonstrate High Morbidity and Mortality. J Immigr Minor Health 2021. [PMID: 33907933 DOI: 10.1007/s10903-021-01205-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
487 Gilman CAL, Koh C, Pavletic S, Heller T. Hepatic Complications. Blood and Marrow Transplantation Long Term Management 2021. [DOI: 10.1002/9781119612780.ch28] [Reference Citation Analysis]
488 Liu H, Shi W, Jin Z, Zhuo R, Dong J, Lao Q, Li S, Pang W. Global, regional, and national mortality trends of female breast cancer by risk factor, 1990-2017. BMC Cancer 2021;21:459. [PMID: 33894746 DOI: 10.1186/s12885-021-08217-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
489 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
490 Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control 2021;28:10732748211009945. [PMID: 33882707 DOI: 10.1177/10732748211009945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
491 Shek D, Chen D, Read SA, Ahlenstiel G. Examining the gut-liver axis in liver cancer using organoid models. Cancer Lett 2021;510:48-58. [PMID: 33891996 DOI: 10.1016/j.canlet.2021.04.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
492 Hu J, Cai D, Zhao Z, Zhong GC, Gong J. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Front Oncol 2021;11:659676. [PMID: 33937074 DOI: 10.3389/fonc.2021.659676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
493 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
494 Paganoni R, Lechel A, Vujic Spasic M. Iron at the Interface of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4097. [PMID: 33921027 DOI: 10.3390/ijms22084097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
495 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
496 Behary J, Raposo AE, Amorim NML, Zheng H, Gong L, McGovern E, Chen J, Liu K, Beretov J, Theocharous C, Jackson MT, Seet-Lee J, McCaughan GW, El-Omar EM, Zekry A. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model. BMC Microbiol 2021;21:113. [PMID: 33858327 DOI: 10.1186/s12866-021-02171-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
497 Qiu YA, Xiong J, Yu T. Role of G Protein-Coupled Estrogen Receptor in Digestive System Carcinomas: A Minireview. Onco Targets Ther 2021;14:2611-22. [PMID: 33888991 DOI: 10.2147/OTT.S291896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
498 Liang Y, Chen X, Tao Z, Ma M, Adah D, Li X, Dai L, Ding W, Fanuel S, Zhao S, Qin L, Chen X, Zhang X. Plasmodium infection prevents recurrence and metastasis of hepatocellular carcinoma possibly via inhibition of the epithelial‑mesenchymal transition. Mol Med Rep 2021;23:418. [PMID: 33846776 DOI: 10.3892/mmr.2021.12057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
499 Luo J, Zheng J, Hao W, Zeng H, Zhang Z, Shao G. lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR-326/hnRNPA2B1 axis in liver cancer. Oncol Lett 2021;21:471. [PMID: 33907581 DOI: 10.3892/ol.2021.12732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
500 Khaitsman DM, Pogrebnyakov IV, Virshke ER, Trofimov IA, Frantsev DY, Dzhanyan IA, Breder VV, Dolgushin BI. Intermediate Stage Hepatocellular Carcinoma Classifications: the Review. jour 2021;4:53-64. [DOI: 10.37174/2587-7593-2021-4-1-53-64] [Reference Citation Analysis]
501 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
502 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
503 Wang SM, Yang PW, Feng XJ, Zhu YW, Qiu FJ, Hu XD, Zhang SH. Apigenin Inhibits the Growth of Hepatocellular Carcinoma Cells by Affecting the Expression of microRNA Transcriptome. Front Oncol 2021;11:657665. [PMID: 33959508 DOI: 10.3389/fonc.2021.657665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
504 Lyu N, Zeng Y, Kong Y, Chen Q, Deng H, Ou S, Bai Y, Tang H, Wang X, Zhao M. Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Ann Transl Med 2021;9:675. [PMID: 33987373 DOI: 10.21037/atm-21-997] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
505 Paik JM, Younossi Y, Henry L, Mishra A, Younossi ZM. Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017. Gastroenterology 2021;160:1845-1846.e3. [PMID: 33421516 DOI: 10.1053/j.gastro.2020.11.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
506 Hirai M, Kinugasa H, Nouso K, Yamamoto S, Terasawa H, Onishi Y, Oyama A, Adachi T, Wada N, Sakata M, Yasunaka T, Onishi H, Shiraha H, Takaki A, Okada H. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. J Gastroenterol Hepatol 2021;36:1118-25. [PMID: 32830343 DOI: 10.1111/jgh.15227] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
507 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18:223-38. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 395] [Cited by in F6Publishing: 364] [Article Influence: 197.5] [Reference Citation Analysis]
508 Li L, Kan X, Zhao Y, Liang B, Ye T, Yang L, Zheng C. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Int J Med Sci 2021;18:2276-84. [PMID: 33967603 DOI: 10.7150/ijms.55510] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
509 Ndiaye H, Liu JY, Hall A, Minogue S, Morgan MY, Waugh MG. Immunohistochemical staining reveals differential expression of ACSL3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases. Biosci Rep 2020;40:BSR20200219. [PMID: 32286604 DOI: 10.1042/BSR20200219] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
510 Sakr MA, Mohamed KAH, Hussein AM, Fouad MH, Allam AS, Safwat E. Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00090-y] [Reference Citation Analysis]
511 Anugwom CM, Allaire M, Akbar SMF, Sultan A, Bollipo S, Mattos AZ, Debes JD. Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 2021;7:23. [PMID: 33884303 DOI: 10.20517/2394-5079.2021.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
512 Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matuse H, Noguchi K, Koga H, Torimura T. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol 2021;14:79. [PMID: 33758660 DOI: 10.3892/mco.2021.2241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
513 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. Liver Cancer 2021. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
514 Shah SC, Zhu X, Dai Q, Peek RM, Shrubsole MJ. Magnesium intake is associated with a reduced risk of incident liver cancer, based on an analysis of the NIH-American Association of Retired Persons (NIH-AARP) Diet and Health Study prospective cohort. Am J Clin Nutr 2021;113:630-8. [PMID: 33330925 DOI: 10.1093/ajcn/nqaa326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
515 Chan LL, Chan SL. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2021;26:39-52. [PMID: 33724135 DOI: 10.1080/14728214.2021.1902503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
516 Niño-Ramírez S, Jaramillo-Arroyave D, Ardila O, Guevara-Casallas LG. Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00011-2. [PMID: 33745755 DOI: 10.1016/j.rgmx.2020.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
517 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
518 Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134:783-91. [PMID: 33734139 DOI: 10.1097/CM9.0000000000001474] [Cited by in Crossref: 308] [Cited by in F6Publishing: 390] [Article Influence: 154.0] [Reference Citation Analysis]
519 Wu X, Wang Q, Lu Y, Zhang J, Yin H, Yi Y. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep 2021;11:6069. [PMID: 33727662 DOI: 10.1038/s41598-021-85688-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
520 Ahn YE, Suh SJ, Yim HJ, Seo YS, Yoon EL, Kim TH, Lee YS, Yim SY, Kim HR, Kang SH, Jung YK, Kim JH, Yeon JE, Um SH, Byun KS. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver. 2021;15:284-294. [PMID: 32307975 DOI: 10.5009/gnl19367] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
521 Li TE, Zhang Z, Wang Y, Xu D, Dong J, Zhu Y, Wang Z. A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:2866-76. [PMID: 33854587 DOI: 10.7150/jca.54408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
522 Wang JH, Li WF, Yong CC, Liu YW, Lu SN, Wang CC. Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection. Sci Rep 2021;11:6041. [PMID: 33723365 DOI: 10.1038/s41598-021-85431-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
523 Kimanya ME, Routledge MN, Mpolya E, Ezekiel CN, Shirima CP, Gong YY. Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data. PLoS One 2021;16:e0247281. [PMID: 33705417 DOI: 10.1371/journal.pone.0247281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
524 Chen X, Meng F, Xiong H, Zou Y. Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis. Front Oncol 2021;11:600027. [PMID: 33777744 DOI: 10.3389/fonc.2021.600027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
525 Honap S, Oben JA. Fat and Hidden Liver Cancer. Clin Liver Dis (Hoboken) 2021;17:49-52. [PMID: 33680434 DOI: 10.1002/cld.1011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
526 Qiu YA, Xiong J, Fu Q, Dong Y, Liu M, Peng M, Jin W, Zhou L, Xu X, Huang X, Fu A, Xu G, Tu G, Yu T. GPER-Induced ERK Signaling Decreases Cell Viability of Hepatocellular Carcinoma. Front Oncol 2021;11:638171. [PMID: 33767999 DOI: 10.3389/fonc.2021.638171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
527 Takagi H, Kaji K, Nishimura N, Ishida K, Ogawa H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. Cells 2021;10:575. [PMID: 33807929 DOI: 10.3390/cells10030575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
528 Lemieux S, Buies A, F Turgeon A, Hallet J, Daigle G, Côté F, Provencher S. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2021;16:e0247958. [PMID: 33662011 DOI: 10.1371/journal.pone.0247958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
529 Okazaki S, Shibuya K, Shiba S, Okamoto M, Miyasaka Y, Osu N, Kawashima M, Kakizaki S, Araki K, Shirabe K, Ohno T. Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe carbon ion radiotherapy for hepatocellular carcinoma in caudate lobe. Hepatol Res 2021;51:303-12. [PMID: 33350034 DOI: 10.1111/hepr.13606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
530 Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschall G, 't Hoen E, Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. J Hepatol 2021;74:535-49. [PMID: 32971137 DOI: 10.1016/j.jhep.2020.09.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
531 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
532 Aujay G, Debordeaux F, Blanc JF, Lapuyade B, Papadopoulos P, Bordenave L, Trillaud H, Pinaquy JB. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma. Nucl Med Commun 2021;42:633-8. [PMID: 33660694 DOI: 10.1097/MNM.0000000000001383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
533 Mohs A, Otto T, Schneider KM, Peltzer M, Boekschoten M, Holland CH, Hudert CA, Kalveram L, Wiegand S, Saez-Rodriguez J, Longerich T, Hengstler JG, Trautwein C. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. J Hepatol 2021;74:638-48. [PMID: 33342543 DOI: 10.1016/j.jhep.2020.09.037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
534 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park JW. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. J Hepatol 2021;74:603-12. [PMID: 33031846 DOI: 10.1016/j.jhep.2020.09.026] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 26.0] [Reference Citation Analysis]
535 Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 2021;28:493-507. [PMID: 33305479 DOI: 10.1111/jvh.13452] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
536 Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs 2021;39:1072-80. [PMID: 33646489 DOI: 10.1007/s10637-021-01090-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
537 Sutton TL, Billingsley KG, Walker BS, Enestvedt CK, Dewey EN, Orloff SL, Mayo SC. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg 2021;221:1182-7. [PMID: 33707077 DOI: 10.1016/j.amjsurg.2021.02.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
538 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
539 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Ohtsuka S, Aramaki T, Uesaka K. Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan. Ann Gastroenterol Surg 2021;5:553-66. [PMID: 34337304 DOI: 10.1002/ags3.12451] [Reference Citation Analysis]
540 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
541 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
542 Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep 2021;11:4493. [PMID: 33627697 DOI: 10.1038/s41598-021-83868-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
543 Sinharay R, Grant AJ, Rivett L, Blackwell R, Mells G, Gelson W. Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era. GastroHep 2021;3:80-7. [PMID: 33821150 DOI: 10.1002/ygh2.443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
544 Zhang X, Hu B, Sun YF, Huang XW, Cheng JW, Huang A, Zeng HY, Qiu SJ, Cao Y, Fan J, Zhou J, Yang XR. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med 2021;11:e335. [PMID: 33634982 DOI: 10.1002/ctm2.335] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
545 Mourad M, Lebossé F, Merle P, Levrero M, Antonini T, Lesurtel M, Ducerf C, Zoulim F, Mabrut JY, Mohkam K. External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort - a retrospective study. Transpl Int 2021;34:535-45. [PMID: 33449394 DOI: 10.1111/tri.13819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
546 Devictor J, Leclercq A, Hazo JB, Burnet E, Jovic L, Bouattour M, Ganne-Carrié N. Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey. Clin Res Hepatol Gastroenterol 2021;45:101650. [PMID: 33609787 DOI: 10.1016/j.clinre.2021.101650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
547 Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant 2021;26:168-75. [PMID: 33650998 DOI: 10.1097/MOT.0000000000000866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
548 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
549 Zhang H, Spencer K, Burley SK, Zheng XFS. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov Today 2021;26:1539-46. [PMID: 33561464 DOI: 10.1016/j.drudis.2021.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
550 Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, Zhang C. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol 2021;161:573-80. [PMID: 33551200 DOI: 10.1016/j.ygyno.2021.01.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
551 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology 2021;73:661-73. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 20.5] [Reference Citation Analysis]
552 Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V 3rd, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open 2021;4:e2037512. [PMID: 33595662 DOI: 10.1001/jamanetworkopen.2020.37512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
553 Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H, Cheng Z, Tao X, Yu C, Li B, Yang C, Wang S, Lv Y, Zhao F, Yao M, Cong W, Wang C, Qin W. PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis. Hepatology 2021;73:644-60. [PMID: 32298475 DOI: 10.1002/hep.31280] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
554 Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, Juengpanich S, Yu H, Shen J, Chen M. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2021;36:302-10. [PMID: 32652685 DOI: 10.1111/jgh.15180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
555 Gu J, Zhang E, Liang B, Zhang Z, Long X, Xiang S, Wang W, Chen X, Huang Z. Use of Direct Liver Stiffness Measurement in Evaluating the Severity of Liver Cirrhosis in Patients with Hepatocellular Carcinoma. World J Surg 2020;44:2777-83. [PMID: 32322938 DOI: 10.1007/s00268-020-05528-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
556 Dulskas A, Kavaliauskas P, Zagminas K, Jancoriene L, Smailyte G. Trends in Incidence and Mortality of Primary Liver Cancer in Lithuania 1998-2015. Int J Environ Res Public Health 2021;18:1191. [PMID: 33572744 DOI: 10.3390/ijerph18031191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
557 Choi J, Lim YS. Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. Kaohsiung J Med Sci 2021;37:262-7. [PMID: 33502828 DOI: 10.1002/kjm2.12364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
558 Marta GN, da Fonseca LG, Braghiroli MI, Moura F, Hoff PM, Sabbaga J. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. Clinics (Sao Paulo) 2021;76:e2498. [PMID: 33503195 DOI: 10.6061/clinics/2021/e2498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
559 Liu C, Xuan LQ, Li K, Feng Z, Lv C, Li XJ, Ji XD, Wan R, Shen J. Shikonin Inhibits Cholangiocarcinoma Cell Line QBC939 by Regulating Apoptosis, Proliferation, and Invasion. Cell Transplant 2021;30:963689720979162. [PMID: 33508949 DOI: 10.1177/0963689720979162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
560 Fiorentino A, Gregucci F, Desideri I, Fiore M, Marino L, Errico A, Di Rito A, Borghetti P, Franco P, Greto D, Donato V. Radiation treatment for adult rare cancers: Oldest and newest indication. Crit Rev Oncol Hematol 2021;159:103228. [PMID: 33508447 DOI: 10.1016/j.critrevonc.2021.103228] [Reference Citation Analysis]
561 Fattahi N, Rezaei N, Asadi-Lari M, Yousefi M, Madadi Z, Gohari K, Sheidaei A, Mohammadi E, Rezaei N, Parsaeian M, Kompani F, Farzadfar F. Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis. PLoS One 2021;16:e0245468. [PMID: 33481849 DOI: 10.1371/journal.pone.0245468] [Reference Citation Analysis]
562 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 889] [Cited by in F6Publishing: 998] [Article Influence: 444.5] [Reference Citation Analysis]
563 Esposito P, Matteo M, Concepcion C, Montanarella M, Matteo J. Portal Vein Tumor Thrombus: No Longer a Death Sentence. Cureus 2021;13:e12845. [PMID: 33628697 DOI: 10.7759/cureus.12845] [Reference Citation Analysis]
564 Zhang Q, Xu X, Wu M, Qin T, Wu S, Liu H. MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis. Front Oncol 2020;10:562019. [PMID: 33542895 DOI: 10.3389/fonc.2020.562019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
565 Burton A, Tataru D, Driver RJ, Bird TG, Huws D, Wallace D, Cross TJS, Rowe IA, Alexander G, Marshall A; HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep 2021;3:100232. [PMID: 33748727 DOI: 10.1016/j.jhepr.2021.100232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
566 Loi M, Comito T, Franzese C, Desideri I, Dominici L, Lo Faro L, Clerici E, Franceschini D, Baldaccini D, Badalamenti M, Reggiori G, Lobefalo F, Scorsetti M. Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy. J Geriatr Oncol 2021;12:1100-3. [PMID: 33461945 DOI: 10.1016/j.jgo.2021.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
567 Gu J, Zhang E, Liang B, Zhang Z, Chen X, Xiong M, Huang Z. Liver Collagen Contents Are Closely Associated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma and Child-Pugh Grade A Liver Function. Ann Surg Oncol 2021;28:4227-35. [PMID: 33452603 DOI: 10.1245/s10434-020-09557-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
568 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
569 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 109] [Cited by in F6Publishing: 109] [Article Influence: 54.5] [Reference Citation Analysis]
570 Barsouk A, Thandra KC, Saginala K, Rawla P, Barsouk A. Chemical Risk Factors of Primary Liver Cancer: An Update. Hepat Med 2020;12:179-88. [PMID: 33447099 DOI: 10.2147/HMER.S278070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
571 Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol 2020;50:1370-9. [PMID: 32719873 DOI: 10.1093/jjco/hyaa130] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
572 Ma H, Li Z, Yuan J, Zhang L, Xie X, Yin X, Chen R, Ren Z. Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation. Gastroenterol Res Pract 2021;2021:8878417. [PMID: 33488700 DOI: 10.1155/2021/8878417] [Reference Citation Analysis]
573 Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, Zhou J, Gong J, Wang J, Wen X, Zhou T, Zhai X, Xu Q, Zhang T, Chen X, Hu G, Wang J, Gao Z, Nan Y, Chen J, Hu B, Zhao J, Lu F. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat 2021;28:20-9. [PMID: 32852885 DOI: 10.1111/jvh.13388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
574 Althubiti M, Alfayez M. Insights on Hepatocellular Carcinoma in Saudi Arabia. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_16] [Reference Citation Analysis]
575 Al-busafi SA, Alnaamani K. Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_17] [Reference Citation Analysis]
576 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 47.0] [Reference Citation Analysis]
577 Mukund A, Bhardwaj K, Choudhury A, Sarin SK. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). J Clin Exp Hepatol 2021;11:674-81. [PMID: 34866846 DOI: 10.1016/j.jceh.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
578 Choudhury S, Aggarwal N, Panda JJ, Mishra J. Emerging Protein and Peptide-Based Nanomaterials for Cancer Therapeutics. Nanotechnology in the Life Sciences 2021. [DOI: 10.1007/978-3-030-74330-7_6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
579 Wong BS, Wong CW, Wong FCL. Human Cancer: Epidemiology, Hallmarks, and Defense Strategies. Locoregional Radionuclide Cancer Therapy 2021. [DOI: 10.1007/978-3-030-56267-0_1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
580 谭 智. Relationship between FBXW7 and the Occurrence of Primary Liver Cancer. ACM 2021;11:1362-1366. [DOI: 10.12677/acm.2021.113194] [Reference Citation Analysis]
581 Malekzadeh R, Poustchi H. Hepatocellular Cancer in Iran. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_14] [Reference Citation Analysis]
582 Craig AJ, Wang XW. Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_6] [Reference Citation Analysis]
583 Pocha PV, Xie C, Pocha C. Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer. Ann Transl Med 2021;9:2. [PMID: 33553295 DOI: 10.21037/atm-20-7534] [Reference Citation Analysis]
584 明 军. Clinical Characteristics and Safety Analysis of Radical Resection of Liver Cancer in Elderly Patients with Liver Cancer. ACM 2021;11:3469-3473. [DOI: 10.12677/acm.2021.118505] [Reference Citation Analysis]
585 Ou Q, Mu H, Zhou C, Zheng Z, Geng J. Liver Diseases. Clinical Molecular Diagnostics 2021. [DOI: 10.1007/978-981-16-1037-0_33] [Reference Citation Analysis]
586 Shih WL, Fang CT, Chen PJ. Chapter XX Antiviral Treatment and Cancer Control. Recent Results Cancer Res 2021;217:325-54. [PMID: 33200371 DOI: 10.1007/978-3-030-57362-1_13] [Reference Citation Analysis]
587 Kim H, Choi J, Kim BH, Youn SY, Kim H, Kim DH, Rha SE. LI-RADS version 2018 in Patients with Prior History of Hepatocellular Carcinoma: Are LR4 Observations Enough for the Diagnosis of Recurrent HCC? Investig Magn Reson Imaging 2021;25:172. [DOI: 10.13104/imri.2021.25.3.172] [Reference Citation Analysis]
588 Kim BH, Park J. Antiviral Therapy in Liver Cancer. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_5] [Reference Citation Analysis]
589 Lin C, Kao J. Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_10] [Reference Citation Analysis]
590 Guo Z, Luo T, Zhao Q, He X. The innovation and clinical application of ischemia-free organ transplantation. Vis Cancer Med 2021;2:6. [DOI: 10.1051/vcm/2021005] [Reference Citation Analysis]
591 Martí-bonmatí L, Torregrosa A. Hepatocellular Carcinoma: Diagnostic Guidelines. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-39021-1_9] [Reference Citation Analysis]
592 Shin J(, Man K, Zhou W. International and global issues – differences in health systems, patient populations, and medical practice. Pragmatic Randomized Clinical Trials 2021. [DOI: 10.1016/b978-0-12-817663-4.00030-1] [Reference Citation Analysis]
593 Zarisfi M, Nguyen T, Nedrow JR, Le A. The Heterogeneity Metabolism of Renal Cell Carcinomas. Adv Exp Med Biol 2021;1311:117-26. [PMID: 34014538 DOI: 10.1007/978-3-030-65768-0_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
594 Gong Y, Li D, Li L, Yang J, Ding H, Zhang C, Wen G, Wu C, Fang Z, Hou S, Yang Y. Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis. Food and Chemical Toxicology 2021;147:111912. [DOI: 10.1016/j.fct.2020.111912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
595 Mosconi C, Golfieri R. Transarterial 90Yttrium Radioembolisation. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-39021-1_14] [Reference Citation Analysis]
596 Méndez Romero A, Habraken S, Sprengers D. Basics of Ablative Radiotherapy: The Background Knowledge Necessary to Practicing Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_7] [Reference Citation Analysis]
597 Chen W, Huang L, Liang J, Ye Y, Yu S, Zhang Y. Long noncoding RNA small nucleolar RNA host gene 15 deteriorates liver cancer via microRNA-18b-5p/LIM-only 4 axis. IUBMB Life 2021;73:349-61. [PMID: 33372376 DOI: 10.1002/iub.2431] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
598 Campigotto M, Giuffrè M, Colombo A, Visintin A, Aversano A, Budel M, Masutti F, Abazia C, Crocé LS. Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature. World J Hepatol 2020; 12(12): 1239-1257 [PMID: 33442451 DOI: 10.4254/wjh.v12.i12.1239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
599 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
600 Bukhari S, Ward K, Styler M. Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. Case Rep Oncol Med 2020;2020:8254236. [PMID: 33343953 DOI: 10.1155/2020/8254236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
601 Okeke E, Mark Davwar P, Mullen B, Duguru M, Agbaji O, Sagay A, Murphy R, Hawkins C. The impact of HIV on hepatocellular cancer survival in Nigeria. Trop Med Int Health 2021;26:335-42. [PMID: 33244817 DOI: 10.1111/tmi.13532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
602 Miller H, Czigany Z, Lurje I, Reichelt S, Bednarsch J, Strnad P, Trautwein C, Roderburg C, Tacke F, Gaisa NT, Knüchel-Clarke R, Neumann UP, Lurje G. Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. Cancers (Basel) 2020;12:E3826. [PMID: 33352897 DOI: 10.3390/cancers12123826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
603 Acosta-Lopez S, Diaz-Bethencourt D, Concepción-Massip T, Martin-Fernandez de Basoa MC, Plata-Bello A, Gonzalez-Rodriguez A, Perez-Hernandez F, Plata-Bello J. The androgen receptor expression and its activity have different relationships with prognosis in hepatocellular carcinoma. Sci Rep 2020;10:22046. [PMID: 33328560 DOI: 10.1038/s41598-020-79177-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
604 Wang R, Zang W, Hu B, Deng D, Ling X, Zhou H, Su M, Jiang J. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study. Technol Cancer Res Treat 2020;19:1533033820980785. [PMID: 33308056 DOI: 10.1177/1533033820980785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
605 Luong AB, Do HQ, Tarchi P, Bonazza D, Bottin C, Cabral LKD, Tran LDC, Doan TPT, Crocè LS, Pham HLT, Tiribelli C, Sukowati CHC. The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations. Cells 2020;9:E2672. [PMID: 33322687 DOI: 10.3390/cells9122672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
606 Umezu T, Tsuneyama K, Kanekura K, Hayakawa M, Tanahashi T, Kawano M, Taguchi YH, Toyoda H, Tamori A, Kuroda M, Murakami Y. Comprehensive analysis of liver and blood miRNA in precancerous conditions. Sci Rep 2020;10:21766. [PMID: 33303811 DOI: 10.1038/s41598-020-78500-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
607 Abugamra S, Yassin A, Abdel-rehim ASM, Sheha DS. Apparent diffusion coefficient for differentiating between benign and malignant hepatic focal lesions. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00068-2] [Reference Citation Analysis]
608 Jeong DY, Kang TW, Min JH, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH, Han H. Effect of Perfluorobutane Microbubbles on Radiofrequency Ablation for Hepatocellular Carcinoma: Suppression of Steam Popping and Its Clinical Implication. Korean J Radiol 2020;21:1077-86. [PMID: 32691543 DOI: 10.3348/kjr.2019.0910] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
609 Qi T, Dong Y, Gao Z, Xu J. Research Progress on the Anti-Cancer Molecular Mechanisms of Huaier. Onco Targets Ther 2020;13:12587-99. [PMID: 33335400 DOI: 10.2147/OTT.S281328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
610 Zhang H, Liang H, Wu S, Zhang Y, Yu Z. MicroRNA-638 induces apoptosis and autophagy in human liver cancer cells by targeting enhancer of zeste homolog 2 (EZH2). Environ Toxicol Pharmacol 2021;82:103559. [PMID: 33290872 DOI: 10.1016/j.etap.2020.103559] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
611 Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
612 Huang SC, Liang JD, Hsu SJ, Hong TC, Yang HC, Kao JH. Direct comparison of biopsy techniques for hepatic malignancies. Clin Mol Hepatol 2021;27:305-12. [PMID: 33317239 DOI: 10.3350/cmh.2020.0301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
613 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 21.7] [Reference Citation Analysis]
614 Liu Z, Shi O, Zhang T, Jin L, Chen X. Disease burden of viral hepatitis A, B, C and E: A systematic analysis. J Viral Hepat 2020;27:1284-96. [PMID: 32741034 DOI: 10.1111/jvh.13371] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
615 Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, Toshima T, Harada N, Ikegami T, Soejima Y, Kohashi K, Oda Y, Mori M. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation. Hepatology 2020;72:1987-99. [PMID: 32112577 DOI: 10.1002/hep.31206] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
616 Han M, Tran BT, Cho H, Oh JK. Economic burden of alcohol-related cancers in the Republic of Korea. Drug Alcohol Depend 2020;217:108295. [PMID: 32979737 DOI: 10.1016/j.drugalcdep.2020.108295] [Reference Citation Analysis]
617 Dhanaraj S, Shah T, O'rourke J, Shetty S. Hepatocellular carcinoma: update on treatment guidelines. Gastrointestinal Nursing 2020;18:S18-S26. [DOI: 10.12968/gasn.2020.18.sup10.s18] [Reference Citation Analysis]
618 van Bömmel F, Denecke T, Seehofer D, Schindler A, Veelken R, Berg T. Diagnostik und Therapie des hepatozellulären Karzinoms. Onkologe 2020;26:1175-1192. [DOI: 10.1007/s00761-020-00858-8] [Reference Citation Analysis]
619 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
620 Siyin ST, Liu T, Li W, Yao N, Xu G, Qu J, Chen Y. A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer. BMC Cancer 2020;20:1168. [PMID: 33256656 DOI: 10.1186/s12885-020-07665-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
621 Onozuka D, Nakamura Y, Tsuji G, Furue M. Mortality in Yusho patients exposed to polychlorinated biphenyls and polychlorinated dibenzofurans: a 50-year retrospective cohort study. Environ Health 2020;19:119. [PMID: 33228703 DOI: 10.1186/s12940-020-00680-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
622 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
623 Takashima H, Moriguchi M, Hayashi N, Ikeda K, Ogiso K, Yokomizo C, Uejima H, Itoh T, Tomioka H, Mizuno S, Shimizu S, Yasui K, Itoh Y. A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. Case Rep Oncol 2020;13:1337-1342. [DOI: 10.1159/000510043] [Reference Citation Analysis]
624 Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:4317-4345. [PMID: 33197225 DOI: 10.1200/jco.20.02672] [Cited by in Crossref: 150] [Cited by in F6Publishing: 174] [Article Influence: 50.0] [Reference Citation Analysis]
625 Mashiko T, Masuoka Y, Nakano A, Tsuruya K, Hirose S, Hirabayashi K, Kagawa T, Nakagohri T. Intussusception due to hematogenous metastasis of hepatocellular carcinoma to the small intestine: A case report. World J Gastroenterol 2020; 26(42): 6698-6705 [PMID: 33268957 DOI: 10.3748/wjg.v26.i42.6698] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
626 Diniz PHC, Silva SDC, Vidigal PVT, Xavier MAP, Lima CX, Faria LC, Ferrari TCA. Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma. J Oncol 2020;2020:4609360. [PMID: 33178273 DOI: 10.1155/2020/4609360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
627 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
628 Mavroudis A, Cholongitas E. Long-Term Survival under Arterial Chemoembolization and Sorafenib of a Patient with Hepatocellular Carcinoma and Tumor Atrial Thrombus: A Case Report and Literature Review. Gastrointest Tumors 2020;7:156-62. [PMID: 33173780 DOI: 10.1159/000509186] [Reference Citation Analysis]
629 Zhang H, Chen X, Yuan Y. Investigation of the miRNA and mRNA Coexpression Network and Their Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:8726567. [PMID: 33274225 DOI: 10.1155/2020/8726567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
630 Wang Q, Liang Y, Peng C, Jiang P. Network Pharmacology-Based Study on the Mechanism of Scutellariae Radix for Hepatocellular Carcinoma Treatment. Evid Based Complement Alternat Med 2020;2020:8897918. [PMID: 33163086 DOI: 10.1155/2020/8897918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
631 Yang J, Zhang X, Liu L, Yang X, Qian Q, Du B. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway. Life Sci 2021;264:118711. [PMID: 33186566 DOI: 10.1016/j.lfs.2020.118711] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
632 Chen S, Jiang T. Preoperative noninvasive assessment for liver fibrosis in hepatocellular carcinoma patients with chronic hepatitis B: Comparison of two-dimensional shear-wave elastography with serum liver fibrosis models. Eur J Radiol 2020;133:109386. [PMID: 33160197 DOI: 10.1016/j.ejrad.2020.109386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
633 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
634 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology 2020;72:1605-16. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 222] [Cited by in F6Publishing: 196] [Article Influence: 74.0] [Reference Citation Analysis]
635 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
636 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650-66. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 278] [Cited by in F6Publishing: 242] [Article Influence: 92.7] [Reference Citation Analysis]
637 Cho MJ, An C, Aljoqiman KS, Choi JY, Lim JS, Park MS, Rhee H, Kim MJ. Diagnostic performance of Liver Imaging Reporting and Data System in patients at risk of both hepatocellular carcinoma and metastasis. Abdom Radiol (NY) 2020;45:3789-99. [PMID: 32440900 DOI: 10.1007/s00261-020-02581-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
638 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
639 Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers (Basel) 2020;12:E3218. [PMID: 33142893 DOI: 10.3390/cancers12113218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
640 Mu XM, Wang W, Wu FY, Jiang YY, Ma LL, Feng J. Comorbidity in Older Patients Hospitalized with Cancer in Northeast China based on Hospital Discharge Data. Int J Environ Res Public Health 2020;17:E8028. [PMID: 33142785 DOI: 10.3390/ijerph17218028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
641 Hara T, Ohara T, Taniguchi M, Sakai T, Oka K, Iwai N, Tsuji T, Okuda T, Komaki T, Sakagami J, Kagawa K. Development of Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 21 Years after Achieving a Sustained Virological Response to Interferon Therapy. Case Reports Hepatol 2020;2020:8824974. [PMID: 33123390 DOI: 10.1155/2020/8824974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
642 Kobayashi K, Uldry E, Demartines N, Halkic N. Liver resections between 2014 and 2020 in the Lausanne University Hospital, Switzerland. Glob Health Med 2020;2:337-42. [PMID: 33330829 DOI: 10.35772/ghm.2020.01059] [Reference Citation Analysis]
643 Chen Y, He C, Wen T, Yan L, Yang J. The prognostic value of aspartate aminotransferase-to-lymphocyte ratio index in early-stage hepatocellular carcinoma after hepatectomy: A propensity-score matched analysis. Asia Pac J Clin Oncol 2021;17:e238-48. [PMID: 33124200 DOI: 10.1111/ajco.13458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
644 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
645 Alanazi SA, Alanazi F, Haq N, Shakeel F, Badran MM, Harisa GI. Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Curr Drug Deliv 2020;17:826-44. [PMID: 32026776 DOI: 10.2174/1567201817666200206104338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
646 Huang Y, Chen S, Qin W, Wang Y, Li L, Li Q, Yuan X. A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma. Front Oncol 2020;10:580513. [PMID: 33251144 DOI: 10.3389/fonc.2020.580513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
647 Lei GY, Shen L, Junnarkar SP, Huey CT, Low J, Shelat VG. Predictors of 90-Day Mortality following Hepatic Resection for Hepatocellular Carcinoma. Visc Med 2021;37:102-9. [PMID: 33981750 DOI: 10.1159/000510811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
648 Mehta R, Tang Qinghe, Tsilimigras DI, Paredes A, Dillhoff M, Cloyd JM, Ejaz A, Tsung A, Spolverato G, Pawlik TM. Long-term outcomes after resection of alcohol-related versus hepatitis-related hepatocellular carcinoma: A SEER-Medicare database analysis. Am J Surg 2021;222:167-72. [PMID: 33131693 DOI: 10.1016/j.amjsurg.2020.10.033] [Reference Citation Analysis]
649 Sun M, Shang P, Bai J, Li S, Li M. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. J Clin Lab Anal 2021;35:e23633. [PMID: 33099812 DOI: 10.1002/jcla.23633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
650 Doan HV, Sritangos P, Iyara R, Chudapongse N. Chrysophyllum cainito stem bark extract induces apoptosis in Human hepatocarcinoma HepG2 cells through ROS-mediated mitochondrial pathway. PeerJ 2020;8:e10168. [PMID: 33088629 DOI: 10.7717/peerj.10168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
651 Fouda MS, Omran MM, Tarek G, Hady A Abdel Wahab A. Development of a novel panel based on micro-RNAs (21, 29a, 200 and 335) and alpha-fetoprotein as diagnostic biomarkers for hepatocellular carcinoma associated with hepatitis C infection. Arab J Gastroenterol 2021;22:28-33. [PMID: 33268243 DOI: 10.1016/j.ajg.2020.08.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
652 Chiang MF, Tseng TK, Shih CW, Yang TH, Wu SY. Clinical and contrast-enhanced image features in the prediction model for the detection of small hepatocellular carcinomas. J Cancer 2020;11:7166-75. [PMID: 33193879 DOI: 10.7150/jca.47245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
653 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
654 Lee YS, Jung YK, Kim JH, Cho SB, Kim DY, Kim MY, Kim HJ, Seo YS, Yoon KT, Hong YM, Lee JH, Lee HW, Yim HJ, Jang BK, Jang ES, Jang JY, Hwang SY. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer 2020;140:19-27. [PMID: 33039810 DOI: 10.1016/j.ejca.2020.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
655 Ocker M, Neureiter D. Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert Rev Gastroenterol Hepatol 2021;15:111-3. [PMID: 32985933 DOI: 10.1080/17474124.2021.1829472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
656 Dumronggittigule W, Han HS, Ahn S, Yoon YS, Cho JY, Choi Y. Laparoscopic versus Open Hepatectomy for Hepatocellular Carcinoma in Elderly Patients: A Single-Institutional Propensity Score Matching Comparison. Dig Surg 2020;37:495-504. [PMID: 33032276 DOI: 10.1159/000510960] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
657 Pang Y, Kartsonaki C, Lv J, Millwood IY, Yu C, Guo Y, Chen Y, Bian Z, Yang L, Chen J, Clarke R, Walters R, Wu S, Li H, Holmes MV, Li L, Chen Z. Observational and Genetic Associations of Body Mass Index and Hepatobiliary Diseases in a Relatively Lean Chinese Population. JAMA Netw Open 2020;3:e2018721. [PMID: 33006619 DOI: 10.1001/jamanetworkopen.2020.18721] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
658 Tokushima Y, Tago M, Tokushima M, Katsuki NE, Iwane S, Eguchi Y, Yamashita SI. Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study. Int J Gen Med 2020;13:743-50. [PMID: 33061544 DOI: 10.2147/IJGM.S268857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
659 Sternby Eilard M, Åberg F. Combination of biomarkers for the detection of hepatocellular carcinoma. Ann Transl Med 2020;8:1283. [PMID: 33209863 DOI: 10.21037/atm-20-5798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
660 Amorim J, França M, Perez-Girbes A, Torregrosa A, Martí-Bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol (NY) 2020;45:3119-28. [PMID: 32173774 DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
661 Wu Z, Guo W, Chen S, Zhuang W. Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy. Invest New Drugs 2021;39:394-9. [PMID: 33006020 DOI: 10.1007/s10637-020-01009-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
662 Keller SB, Suo D, Wang YN, Kenerson H, Yeung RS, Averkiou MA. Image-Guided Treatment of Primary Liver Cancer in Mice Leads to Vascular Disruption and Increased Drug Penetration. Front Pharmacol 2020;11:584344. [PMID: 33101038 DOI: 10.3389/fphar.2020.584344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
663 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
664 Wei H, Jiang H, Liu X, Qin Y, Zheng T, Liu S, Zhang X, Song B. Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma? Eur J Radiol 2020;132:109312. [PMID: 33022551 DOI: 10.1016/j.ejrad.2020.109312] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
665 Caviglia GP, Ciruolo M, Olivero A, Carucci P, Rolle E, Rosso C, Abate ML, Risso A, Ribaldone DG, Tandoi F, Saracco GM, Bugianesi E, Gaia S. Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2776. [PMID: 32998218 DOI: 10.3390/cancers12102776] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
666 Liu T, Siyin ST, Yao N, Xu G, Chen YT, Duan N, Li W, Qu J, Liu S. Risk of primary liver cancer associated with gallstones and cholecystectomy: A competing risks analysis. Medicine (Baltimore) 2020;99:e22428. [PMID: 32991479 DOI: 10.1097/MD.0000000000022428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
667 Shen M, Shen Y, Fan X, Men R, Ye T, Yang L. Roles of Macrophages and Exosomes in Liver Diseases. Front Med (Lausanne) 2020;7:583691. [PMID: 33072790 DOI: 10.3389/fmed.2020.583691] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
668 Melchor SJ, Hatter JA, Castillo ÉAL, Saunders CM, Byrnes KA, Sanders I, Abebayehu D, Barker TH, Ewald SE. T. gondii infection induces IL-1R dependent chronic cachexia and perivascular fibrosis in the liver and skeletal muscle. Sci Rep 2020;10:15724. [PMID: 32973293 DOI: 10.1038/s41598-020-72767-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
669 Xu H, Zhang Q, Tan Y, Zhang Y, Wei J, Wang L, Xie B. Efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer and their effects on hepatitis B virus and liver function. All Life 2020;13:524-31. [DOI: 10.1080/26895293.2020.1819444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
670 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
671 Montasser IF, Ibrahim AA, Farid HM, Al Balakosy AM. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? Clin Res Hepatol Gastroenterol 2021;45:101517. [PMID: 32900667 DOI: 10.1016/j.clinre.2020.07.022] [Reference Citation Analysis]
672 Ho JL, Konda A, Rahman J, Harris E, Korn R, Sabir A, Bawany B, Gulati R, Harris GJ, Boswell WD, Fong Y, Rahmanuddin S. Comparative analysis of three-dimensional volume rendering and maximum intensity projection for preoperative planning in liver cancer. Eur J Radiol Open 2020;7:100259. [PMID: 32944595 DOI: 10.1016/j.ejro.2020.100259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
673 Ma WK, Voss DM, Scharner J, Costa ASH, Lin K, Jeon HY, Wilkinson JE, Jackson M, Rigo F, Bennett CF, Krainer AR. ASO-based PKM Splice-switching Therapy Inhibits Hepatocellular Carcinoma Cell Growth.. [DOI: 10.1101/2020.09.01.278580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
674 Ogawa E, Takayama K, Hiramine S, Hayashi T, Toyoda K. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Aliment Pharmacol Ther 2020;52:866-76. [PMID: 32697871 DOI: 10.1111/apt.15976] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
675 Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol 2020;73:523-32. [PMID: 32335166 DOI: 10.1016/j.jhep.2020.04.008] [Cited by in Crossref: 152] [Cited by in F6Publishing: 137] [Article Influence: 50.7] [Reference Citation Analysis]
676 Gabr A, Entezari P, Riaz A, Salem R, Lewandowski RJ. Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology 2020;2:113-25. [DOI: 10.1016/j.yacr.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
677 Luo B, Yun X, Li J, Fan R, Guo WW, Liu C, Lin YD, Ge YY, Zeng X, Bi SQ, Nong WX, Zhang QM, Xie XX. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Curr Med Sci 2020;40:719-28. [PMID: 32862383 DOI: 10.1007/s11596-020-2241-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
678 Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020;8. [PMID: 32847986 DOI: 10.1136/jitc-2020-000987] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
679 Cossiga V, Guarino M, Morisco F, Caporaso N. Risk stratification of HCC occurrence after HCV eradication: a complicate plot of risk factors related and unrelated to the previous viral disease. Hepatobiliary Surg Nutr 2020;9:511-3. [PMID: 32832506 DOI: 10.21037/hbsn.2019.11.27] [Reference Citation Analysis]
680 Campbell C, Wang T, Mcnaughton A, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis.. [DOI: 10.1101/2020.08.21.20179234] [Reference Citation Analysis]
681 Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. Eur Radiol 2021;31:1608-19. [PMID: 32827266 DOI: 10.1007/s00330-020-07171-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
682 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Du H, Bennett D, Bian Z, Chen Y, Yang L, Turnbull I, Wang H, Li H, Holmes MV, Chen J, Chen Z, Li L. Association of physical activity with risk of hepatobiliary diseases in China: a prospective cohort study of 0.5 million people. Br J Sports Med 2021;55:1024-33. [PMID: 32826226 DOI: 10.1136/bjsports-2020-102174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
683 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
684 El-Garawani IM, El-Sabbagh SM, Abbas NH, Ahmed HS, Eissa OA, Abo-Atya DM, Khalifa SAM, El-Seedi HR. A newly isolated strain of Halomonas sp. (HA1) exerts anticancer potential via induction of apoptosis and G2/M arrest in hepatocellular carcinoma (HepG2) cell line. Sci Rep 2020;10:14076. [PMID: 32826930 DOI: 10.1038/s41598-020-70945-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
685 Saeed A, Hildebrand H, Park R, Al-Jumayli M, Abbasi S, Melancon T, Saeed A, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Sun W. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. J Clin Med 2020;9:E2682. [PMID: 32824968 DOI: 10.3390/jcm9092682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
686 Marini TJ, Oppenheimer DC, Baran TM, Rubens DJ, Toscano M, Drennan K, Garra B, Miele FR, Garra G, Noone SJ, Tamayo L, Carlotto C, Trujillo L, Waks E, Garra K, Egoavil MS, Berrospi J, Castaneda B. New Ultrasound Telediagnostic System for Low-Resource Areas: Pilot Results From Peru. J Ultrasound Med 2021;40:583-95. [PMID: 32798267 DOI: 10.1002/jum.15420] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
687 Wu V, McArthur MA, Allen A, Manon L, Xie KL. Rare primary hepatic malignancies: A case-based review. Clin Imaging 2021;69:196-204. [PMID: 32919206 DOI: 10.1016/j.clinimag.2020.08.004] [Reference Citation Analysis]
688 Fan J, Liu Z, Mao X, Tong X, Zhang T, Suo C, Chen X. Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017. Cancer Med 2020;9:6875-87. [PMID: 32750217 DOI: 10.1002/cam4.3338] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
689 Smith WH, Law AS, Hulkower M, McGee HM, Lehrer EJ, Schwartz M, Taouli B, Sung M, Buckstein M. The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Acta Oncol 2020;59:940-3. [PMID: 32441551 DOI: 10.1080/0284186X.2020.1769860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
690 Lu HS, Hsin IF, Chen PH, Yang TC, Chang CY, Huang YH, Hou MC. The indocyanine green retention test as a noninvasive marker for esophageal varices in patients with hepatocellular carcinoma. J Chin Med Assoc 2020;83:737-42. [PMID: 32649412 DOI: 10.1097/JCMA.0000000000000378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
691 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
692 Merchante N, Rodríguez-Fernández M, Figueruela B, Rodríguez-Arrondo F, Revollo B, Ibarra S, Téllez F, Merino E, Montero-Alonso M, Galindo MJ, Rivero-Juárez A, Santos IL, Delgado-Fernández M, García-Deltoro M, Vera-Méndez FJ, García MA, Aguirrebengoa K, Portu J, Ríos-Villegas MJ, Villalobos M, Alemán-Valls MR, Mínguez C, Galera C, Macías J, Pineda JA; GEHEP-002 Study Group. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. AIDS 2020;34:1497-507. [PMID: 32675563 DOI: 10.1097/QAD.0000000000002578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
693 Iacuzzi V, Zanchetta M, Gagno S, Poetto AS, Orleni M, Marangon E, Guardascione M, Foltran L, Posocco B, Toffoli G. A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. Journal of Pharmaceutical and Biomedical Analysis 2020;187:113358. [DOI: 10.1016/j.jpba.2020.113358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
694 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
695 Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. Liver Cancer. 2020;9:563-582. [PMID: 33083281 DOI: 10.1159/000508568] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 17.3] [Reference Citation Analysis]
696 Sorop A, Iacob R, Iacob S, Constantinescu D, Chitoiu L, Fertig TE, Dinischiotu A, Chivu-Economescu M, Bacalbasa N, Savu L, Gheorghe L, Dima S, Popescu I. Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepatocellular Carcinoma Screening. Front Genet 2020;11:712. [PMID: 32793278 DOI: 10.3389/fgene.2020.00712] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
697 Li L, Liu JD, Gao GD, Zhang K, Song YW, Li HB. Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR. Cancer Med 2020;9:6399-410. [PMID: 32691991 DOI: 10.1002/cam4.3285] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
698 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
699 Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56. [PMID: 32615109 DOI: 10.1016/S1470-2045(20)30224-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 24.3] [Reference Citation Analysis]
700 Kim SS, Baek GO, Ahn HR, Sung S, Seo CW, Cho HJ, Nam SW, Cheong JY, Eun JW. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol Oncol. 2020;14:2646-2659. [PMID: 32525601 DOI: 10.1002/1878-0261.12745] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
701 Vo TK, Ta QTH, Chu QT, Nguyen TT, Vo VG. Anti-Hepatocellular-Cancer Activity Exerted by β-Sitosterol and β-Sitosterol-Glucoside from Indigofera zollingeriana Miq. Molecules 2020;25:E3021. [PMID: 32630623 DOI: 10.3390/molecules25133021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
702 Belay AS, Abateneh DD, Yehualashet SS, Kebede KM. Hepatitis B Virus Infection and Associated Factors Among Adults in Southwest Ethiopia: Community-Based Cross-Sectional Study. Int J Gen Med 2020;13:323-32. [PMID: 32606897 DOI: 10.2147/IJGM.S259375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
703 Liu Y, Li Y, Wang X, Huang Y, Zhang Q, Shi K, Ran C, Hou J, Wang X. Fufang Banmao Capsule, a Traditional Chinese Medicinal Formulation, Enhances the Survival of Patients with Hepatocellular Carcinoma and Vp3-4 Portal Vein Tumor Thrombosis Undergoing Supportive Treatment. J Altern Complement Med 2020;26:956-65. [PMID: 32614605 DOI: 10.1089/acm.2019.0334] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
704 Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res 2020;12:5323-30. [PMID: 32753950 DOI: 10.2147/CMAR.S254580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
705 Shiha G, Mousa N, Soliman R, Nnh Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. J Viral Hepat 2020;27:671-9. [PMID: 32050037 DOI: 10.1111/jvh.13276] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
706 Su C, Jin C, Han J, Hu X, Shi D, Meng F. Ultrasonographic assessment of right heart intracardiac mass in patients with hepatitis B virus infection. Eur J Gastroenterol Hepatol 2020;32:838-43. [PMID: 31725029 DOI: 10.1097/MEG.0000000000001589] [Reference Citation Analysis]
707 Zheng S, Zhang Y, Chen S, Zhang Z, Chen F, Zhang Z, Hu Z, Tian J, Wang L. A preliminary study of dual-band confocal laser endomicroscopy combined with image mosaic in the diagnosis of liver cancer. Nanomedicine 2020;29:102250. [PMID: 32619706 DOI: 10.1016/j.nano.2020.102250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
708 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
709 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals. J Infect Dis 2020:jiaa359. [PMID: 32584386 DOI: 10.1093/infdis/jiaa359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
710 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
711 Yu L, Wang F, Tai M, Li J, Gong S, Zhou Z, Yin X, Gu X, Li C. 6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway. Eur J Pharmacol 2020;882:173299. [PMID: 32589884 DOI: 10.1016/j.ejphar.2020.173299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
712 Dahlgren D, Lennernäs H. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules 2020;25:E2861. [PMID: 32575828 DOI: 10.3390/molecules25122861] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
713 Shan QL, Chen NN, Meng GZ, Qu F. Overexpression of lncRNA MT1JP Mediates Apoptosis and Migration of Hepatocellular Carcinoma Cells by Regulating miR-24-3p. Cancer Manag Res 2020;12:4715-24. [PMID: 32606962 DOI: 10.2147/CMAR.S249582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
714 Mårdh O, Quinten C, Amato-Gauci AJ, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline. Infect Dis (Lond) 2020;52:625-37. [PMID: 32644030 DOI: 10.1080/23744235.2020.1766104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
715 Lim Z, Teo J, Tan A, Siam TS, Mohamed R, Goh K, Lee Y, Lai W, Lim T. Cascade of care, awareness and treatment of Chronic Hepatitis B in Malaysia- findings from a community-based screening campaign.. [DOI: 10.1101/2020.06.15.20131409] [Reference Citation Analysis]
716 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 15.3] [Reference Citation Analysis]
717 Baumeister SE, Leitzmann MF, Linseisen J, Schlesinger S. Physical Activity and the Risk of Liver Cancer: A Systematic Review and Meta-Analysis of Prospective Studies and a Bias Analysis. J Natl Cancer Inst 2019;111:1142-51. [PMID: 31168582 DOI: 10.1093/jnci/djz111] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
718 Hajighasemlou S, Nikbakht M, Pakzad S, Muhammadnejad S, Gharibzadeh S, Mirmoghtadaei M, Zafari F, Seyhoun I, Ai J, Verdi J. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evid Based Complement Alternat Med 2020;2020:9602728. [PMID: 32617114 DOI: 10.1155/2020/9602728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
719 Huang W, Yu D, Wang M, Han Y, Lin J, Wei D, Cai J, Li B, Chen P, Zhang X. ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma. Cell Prolif 2020;53:e12836. [PMID: 32537856 DOI: 10.1111/cpr.12836] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
720 Ali HS, Boshra MS, El Meteini MS, Shafei AE, Matboli M. lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma. Genomics 2020;112:3306-14. [PMID: 32544548 DOI: 10.1016/j.ygeno.2020.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
721 García-Marchena N, Maza-Quiroga R, Serrano A, Barrios V, Requena-Ocaña N, Suárez J, Chowen JA, Argente J, Rubio G, Torrens M, López-Gallardo M, Marco EM, Castilla-Ortega E, Santín LJ, Rodríguez de Fonseca F, Pavón FJ, Araos P. Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases. J Psychopharmacol 2020;34:1250-60. [PMID: 32536325 DOI: 10.1177/0269881120928176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
722 Bai Y, Xie F, Miao F, Long J, Huang S, Huang H, Lin J, Wang D, Yang X, Bian J, Mao J, Wang X, Mao Y, Sang X, Zhao H. The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. Aging (Albany NY) 2019;11:5158-72. [PMID: 31339860 DOI: 10.18632/aging.102110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
723 Adadey SM, Languon S, Ayee R, Quansah DN, Quaye O. Incidence and mortality of cancer in the Volta Region of Ghana. Exp Biol Med (Maywood) 2020;245:1058-65. [PMID: 32498552 DOI: 10.1177/1535370220931514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
724 Mak D, Kramvis A. Molecular characterization of hepatitis B virus isolated from Black South African cancer patients, with and without hepatocellular carcinoma. Arch Virol 2020;165:1815-25. [PMID: 32504396 DOI: 10.1007/s00705-020-04686-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
725 Tian Y, Li T, Qi S, Alhourani H, Luo B, Chenqin J, Fu Q, Peng Y, Wu J. The impact of metabolic syndrome (MetS) on surgical outcome for patients with mostly HBV-related hepatocellular carcinoma (HCC) underwent hepatectomy. J Surg Oncol 2020. [PMID: 32502302 DOI: 10.1002/jso.26055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
726 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
727 Gümüş ZZ, Topal F, Taşdemir Ü, Günay S, Çamyar H, Akbulut S, Saritaş Yüksel E, Vatansever S, Topal FE. Efficacy of P2/MS and AFP in Early Prediction of Hepatocellular Carcinoma Recurrence. Konuralp Tıp Dergisi 2020. [DOI: 10.18521/ktd.632438] [Reference Citation Analysis]
728 Diniz PHC, Silva SDDC, Faria LC, Vidigal PVT, Ferrari TCA. Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment. Clinics (Sao Paulo) 2020;75:e1529. [PMID: 32520221 DOI: 10.6061/clinics/2020/e1529] [Reference Citation Analysis]
729 Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) score: The current status. The Surgeon 2020;18:178-86. [DOI: 10.1016/j.surge.2019.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
730 Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020;71:1910-22. [PMID: 31610027 DOI: 10.1002/hep.30988] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
731 Smith WH, Ru M, Mcgee HM, Sung M, Rosenzweig KE, Buckstein M. Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma. J Radiat Oncol 2020;9:45-52. [DOI: 10.1007/s13566-020-00419-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
732 Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Dig Dis Interv 2020;4:134-47. [PMID: 32832829 DOI: 10.1055/s-0040-1712146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
733 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 73] [Cited by in F6Publishing: 89] [Article Influence: 24.3] [Reference Citation Analysis]
734 Ha SY, Choi S, Park S, Kim JM, Choi GS, Joh JW, Park CK. Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma. Virchows Arch 2020;477:807-16. [PMID: 32483662 DOI: 10.1007/s00428-020-02841-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
735 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
736 Jiang H, Zhao L, Chen Y, Sun L. A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23377. [PMID: 32474975 DOI: 10.1002/jcla.23377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
737 Yi Q, Liu J, Alexia K, Li J, Luo H, Sun J. [Over-expression of miR-144 inhibits invasion of liver cancer SMMC-7721 cells in vitro by suppressing TLR/MyD88 pathway]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:765-71. [PMID: 32897198 DOI: 10.12122/j.issn.1673-4254.2020.05.25] [Reference Citation Analysis]
738 Hou PP, Luo LJ, Chen HZ, Chen QT, Bian XL, Wu SF, Zhou JX, Zhao WX, Liu JM, Wang XM, Zhang ZY, Yao LM, Chen Q, Zhou D, Wu Q. Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment. Mol Cell 2020;78:1192-1206.e10. [PMID: 32470318 DOI: 10.1016/j.molcel.2020.05.004] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 19.3] [Reference Citation Analysis]
739 Shabangu CS, Huang JF, Hsiao HH, Yu ML, Chuang WL, Wang SC. Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases. Int J Mol Sci 2020;21:E3732. [PMID: 32466319 DOI: 10.3390/ijms21103732] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
740 Khan H, Jia W, Yu Z, Zaib T, Feng J, Jiang Y, Song H, Bai Y, Yang B, Feng H. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2. Biomed Pharmacother 2020;128:110244. [PMID: 32464306 DOI: 10.1016/j.biopha.2020.110244] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
741 Ye Z, Wang S, Chen W, Zhang X, Chen J, Jiang J, Wang M, Zhang L, Xuan Z. Fat mass and obesity-associated protein promotes the tumorigenesis and development of liver cancer. Oncol Lett 2020;20:1409-17. [PMID: 32724383 DOI: 10.3892/ol.2020.11673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
742 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
743 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
744 Elhendawy M, Abdul-Baki EA, Abd-Elsalam S, Hagras MM, Zidan AA, Abdel-Naby AY, Watny M, Elkabash IA, Salem ML, Elshanshoury M, Soliman S, Abdou S. MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers. Mol Biol Rep 2020;47:4945-53. [PMID: 32430845 DOI: 10.1007/s11033-020-05521-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
745 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
746 Peng C, Teng W, Hsieh Y, Jeng W, Huang C, Lui K, Hung C, Chen Y, Lin C, Lin C, Lin S, Sheen I. Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. Adv in Digestive Med 2020;7:83-92. [DOI: 10.1002/aid2.13182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
747 Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M. GSK-3 in liver diseases: Friend or foe? Biochim Biophys Acta Mol Cell Res 2020;1867:118743. [PMID: 32417256 DOI: 10.1016/j.bbamcr.2020.118743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
748 Allaire M, El Hajj W, Brichler S, Diallo K, Fanica D, Blaise L, Nkontchou G, Grando V, Arbadi F, Nahon P, Ziol M, Nault JC, Ganne-Carrié N. Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West. Clin Res Hepatol Gastroenterol 2021;45:101436. [PMID: 32418851 DOI: 10.1016/j.clinre.2020.03.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
749 Du Z, Chen W, Xia Q, Shi O, Chen Q. Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study. Biomark Res 2020;8:16. [PMID: 32435498 DOI: 10.1186/s40364-020-00195-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 6.7] [Reference Citation Analysis]
750 Chen ZY, Wang T, Gan X, Chen SH, He YT, Wang YQ, Zhang KH. Cytoskeleton-associated membrane protein 4 is upregulated in tumor tissues and is associated with clinicopathological characteristics and prognosis in hepatocellular carcinoma. Oncol Lett 2020;19:3889-98. [PMID: 32382336 DOI: 10.3892/ol.2020.11499] [Reference Citation Analysis]
751 da Costa AC, Sodergren M, Jayant K, Santa Cruz F, Spalding D, Pai M, Habib N. Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World J Gastroenterol 2020; 26(17): 2040-2048 [PMID: 32536773 DOI: 10.3748/wjg.v26.i17.2040] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
752 Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS One 2020;15:e0232449. [PMID: 32379785 DOI: 10.1371/journal.pone.0232449] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
753 Huang YY, Jiang HX, Shi QY, Qiu X, Wei X, Zhang XL, Qin SY. miR-145 Inhibits Th9 Cell Differentiation by Suppressing Activation of the PI3K/Akt/mTOR/p70S6K/HIF-1α Pathway in Malignant Ascites from Liver Cancer. Onco Targets Ther 2020;13:3789-800. [PMID: 32440147 DOI: 10.2147/OTT.S245346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
754 Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. J Clin Gastroenterol 2020;54:459-67. [PMID: 30672817 DOI: 10.1097/MCG.0000000000001172] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
755 Gao Y, Li Z, Hong Y, Li T, Hu X, Sun L, Chen Z, Chen Z, Luo Z, Wang X, Kong J, Li G, Wang H, Leo HL, Yu H, Xi L, Guo Q. Decellularized liver as a translucent ex vivo model for vascular embolization evaluation. Biomaterials 2020;240:119855. [DOI: 10.1016/j.biomaterials.2020.119855] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
756 Mu XM, Wang W, Jiang YY, Feng J. Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. Int J Environ Res Public Health 2020;17:E3108. [PMID: 32365650 DOI: 10.3390/ijerph17093108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
757 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
758 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
759 Liu HY, Lee Y, McLean K, Leggett D, Hodgkinson P, Fawcett J, Mott R, Stuart K, Pryor D. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service. Clin Oncol (R Coll Radiol) 2020;32:e194-202. [PMID: 32345457 DOI: 10.1016/j.clon.2020.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
760 De Benedittis C, Bellan M, Crevola M, Boin E, Barbaglia MN, Mallela VR, Ravanini P, Ceriani E, Fangazio S, Sainaghi PP, Burlone ME, Minisini R, Pirisi M. Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:4216451. [PMID: 32382265 DOI: 10.1155/2020/4216451] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
761 Sun JY, Zhang XY, Cao YZ, Zhou X, Gu J, Mu XX. Diagnostic and prognostic value of circular RNAs in hepatocellular carcinoma. J Cell Mol Med 2020;24:5438-45. [PMID: 32281724 DOI: 10.1111/jcmm.15258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
762 Yammine K, Kamar F, Nasser J, Tayar C, Ghosn M, Chehade F, Daher J, Nicolas G. Single-Institution Experience with Selective Internal Radiation Therapy (SIRT) for the Treatment of Primary and Secondary Hepatic Tumors. Cureus. [DOI: 10.7759/cureus.7628] [Reference Citation Analysis]
763 Li TH, Tsai YL, Hsu CF, Liu CW, Huang CC, Yang YY, Tsai HC, Huang SF, Hsieh YC, Liu HM, Lee TY, Hou MC, Tsai CY, Lin HC. Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis. Gastroenterol Res Pract 2020;2020:1892584. [PMID: 32454812 DOI: 10.1155/2020/1892584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
764 Wang P, Peng J, Gong Y, Shen N. CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population. Mol Biol Rep 2020;47:3361-8. [PMID: 32248384 DOI: 10.1007/s11033-020-05408-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
765 Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology 2020;71:1247-61. [PMID: 31378984 DOI: 10.1002/hep.30889] [Cited by in Crossref: 143] [Cited by in F6Publishing: 149] [Article Influence: 47.7] [Reference Citation Analysis]
766 Zarrinpar A, Kim UB, Boominathan V. Phenotypic Response and Personalized Medicine in Liver Cancer and Transplantation: Approaches to Complex Systems. Adv Therap 2020;3:1900167. [DOI: 10.1002/adtp.201900167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
767 McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling Progress Toward Elimination of Hepatitis B in Australia. Hepatology 2020;71:1170-81. [PMID: 31419332 DOI: 10.1002/hep.30899] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
768 Ko KL, To WP, Mak LY, Seto WK, Ning Q, Fung J, Lai CL, Yuen MF. A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. J Viral Hepat 2020;27:397-406. [PMID: 31755196 DOI: 10.1111/jvh.13237] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
769 Augenfeld Z, Lin M, Chapiro J, Duncan J. Automatic Multimodal Registration via Intraprocedural Cone-Beam CT Segmentation using MRI Distance Maps. 2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI) 2020. [DOI: 10.1109/isbi45749.2020.9098619] [Reference Citation Analysis]
770 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 17.3] [Reference Citation Analysis]
771 Itoh S, Yoshizumi T, Mori M. Is sarcopenic obesity superior to sarcopenia as a predicting indicator in patients with hepatocellular carcinoma following hepatic resection? Hepatobiliary Surg Nutr 2020;9:202-4. [PMID: 32355679 DOI: 10.21037/hbsn.2019.09.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
772 O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, Asiki G, Seeley J, Matthews PC, Newton R. Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ Open 2020;10:e032890. [PMID: 32234740 DOI: 10.1136/bmjopen-2019-032890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
773 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
774 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
775 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
776 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
777 Unfried JP, Fortes P. LncRNAs in HCV Infection and HCV-Related Liver Disease. Int J Mol Sci 2020;21:E2255. [PMID: 32214045 DOI: 10.3390/ijms21062255] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
778 Liu Z, Suo C, Mao X, Jiang Y, Jin L, Zhang T, Chen X. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. Cancer 2020;126:2267-78. [PMID: 32201944 DOI: 10.1002/cncr.32789] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 14.7] [Reference Citation Analysis]
779 Polekhin AS, Tarazov PG, Polikarpov AA, Granov DA. TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA ON ADVANCED LIVER CIRRHOSIS. VESTNIK KHIRURGII IMENI I I GREKOVA 2020;178:29-35. [DOI: 10.24884/0042-4625-2019-178-6-29-35] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
780 Bamodu OA, Chang HL, Ong JR, Lee WH, Yeh CT, Tsai JT. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. Cells 2020;9:E746. [PMID: 32197467 DOI: 10.3390/cells9030746] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
781 Zhao HQ, Dong BL, Zhang M, Dong XH, He Y, Chen SY, Wu B, Yang XJ. Increased KIF21B expression is a potential prognostic biomarker in hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(3): 276-288 [PMID: 32206178 DOI: 10.4251/wjgo.v12.i3.276] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
782 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
783 Shim JH. Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease? Clin Mol Hepatol 2020;26:183-4. [PMID: 32160729 DOI: 10.3350/cmh.2020.0042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
784 Wu CH, Chen CY, Yeh CT, Lin KH. Radiosensitization of Hepatocellular Carcinoma through Targeting Radio-Associated MicroRNA. Int J Mol Sci 2020;21:E1859. [PMID: 32182776 DOI: 10.3390/ijms21051859] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
785 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
786 Song SS, Ying JF, Zhang YN, Pan HY, He XL, Hu ZM, Wang HJ, Dou XB, Mou XZ. High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:3181-8. [PMID: 32256814 DOI: 10.3892/ol.2020.11430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
787 Mahmud S, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatol Commun. 2020;4:577-587. [PMID: 32258952 DOI: 10.1002/hep4.1491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
788 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 25.3] [Reference Citation Analysis]
789 Giannitrapani L, Zerbo M, Amodeo S, Pipitone E, Galia M, Li Cavoli TV, Minissale MG, Licata A, Schiavone C, Brancatelli G, Montalto G, Soresi M. The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. Biomed Res Int 2020;2020:5309307. [PMID: 32185209 DOI: 10.1155/2020/5309307] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
790 Hao YJ, Sun HB, Li HW, Chen BJ, Chen XL, Ma L, Li YL. Application of positive behavior management in patients after breast cancer surgery. World J Clin Cases 2020; 8(4): 689-699 [PMID: 32149053 DOI: 10.12998/wjcc.v8.i4.689] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
791 Yang J, Li Y, Liu Q, Li L, Feng A, Wang T, Zheng S, Xu A, Lyu J. Brief introduction of medical database and data mining technology in big data era. J Evid Based Med 2020;13:57-69. [PMID: 32086994 DOI: 10.1111/jebm.12373] [Cited by in Crossref: 134] [Cited by in F6Publishing: 158] [Article Influence: 44.7] [Reference Citation Analysis]
792 Wang Y, Yan P, Fu T, Yuan J, Yang G, Liu Y, Zhang ZJ. The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies. Diabetes Metab 2020;46:461-71. [PMID: 32097717 DOI: 10.1016/j.diabet.2020.02.003] [Cited by in Crossref: 9]&nbs